DermWorld Weekly

Nov. 11, 2026:

• Low-dose oral minoxidil for pediatric hair disorders: an international consensus statement

• DermWorld What’s Hot: Melanoma vaccine

• Dermoscopic pitfall in pigmented BCC

• Treatment approaches for keloids, hypertrophic scars in skin of color

• Efficacy of laser therapy in melasma treatment

Nov. 4, 2026:

• Oral retinol supplementation for actinic keratosis

• DermWorld Insights and Inquiries: X-linked ichthyosis — an affair of the heart

• Die-off reaction of Demodex mites after treating demodicosis with oral ivermectin

• Baricitinib and ritlecitinib in alopecia areata

• A review of loose anagen hair syndrome

Oct. 28, 2026:

• Spironolactone vs. bicalutamide for female pattern hair loss

• DermWorld What’s Hot: Topical statins for porokeratosis

• GLP-1s and clinical outcomes in hidradenitis suppurativa

• Short-term abrocitinib with topical therapy for pruritus in older patients with AD

• Measles risk, MMR vaccination timing in patients on immunosuppressive therapy

Oct. 21, 2026:

• Adverse events of topical finasteride for androgenetic alopecia

• DermWorld What’s Hot: Kratom-induced hyperpigmentation

• AAD member appointed to Physician-Focused Payment Model Technical Advisory Committee

• iPLEDGE changes delayed until Nov. 15

• OTC skin creams contain undeclared active ingredients

• Dermoscopic pitfall in pigmented BCC

Oct. 14, 2026:

• JAK inhibitors in older adults: A practical guide to drug selection, dosing

• DermWorld What’s Hot: Understanding the ‘Big Wellness’ industry

• Former AAD President Seemal R. Desai, MD, FAAD, honored with EADV International Award

• FDA expands indication for urticaria drug

• Can botulinum toxin improve facial hypertrophic scars?

• Is there an association between CCCA and type 2 diabetes?

Oct. 7, 2026:

• Isotretinoin and risk of inflammatory bowel disease

• DermWorld Insights and Inquiries: Nevus lipomatosus superficialis needs deeper understanding

• Cold-sensitive acral hand lesions

• FDA expands drug approval to adolescents with alopecia areata

• Acitretin and methotrexate in vulvar lichen sclerosus

Sept. 30, 2026:

• Oral finasteride, dutasteride for female pattern hair loss and frontal fibrosing alopecia

• DermWorld What’s Hot: Finding the right skin cancer screening cadence

• Academy mourns the passing of W. Mitchell Sams Jr., MD

• Which JAK inhibitor is most effective for atopic dermatitis?

• Patch testing for contact dermatitis: Insights from DataDerm

Sept. 23, 2026:

• Local hyperthermia with hydrogen peroxide for warts

• DermWorld What’s Hot: Molecular profiling of CTCL

• AAD releases new AD diagnostic testing guidelines

• Pediatric use of JAK inhibitors and height

• Comparing treatments for keloids

• Now available: 2025 MIPS performance feedback, final scores, and targeted review

Sept. 16, 2026:

• Does topical finasteride improve hair growth in androgenetic alopecia?

• DermWorld What’s Hot: Recalcitrant warts

• Apply to become next JAAD Deputy Editor-in-Chief

• Efficacy of monotherapies for psoriatic nails

Sept. 9, 2026:

• Does estrogen therapy affect menopausal hair loss?

• DermWorld What’s Hot: Discordance in diagnosis of melanocytic neoplasms

• Derm Coding Consult: VA announces new precertification requirement for Regions 1, 2, and 3

• Nationwide epinephrine recall

• Dose reduction of dupilumab vs. JAK inhibitors in atopic dermatitis

Sept. 2, 2026:

• Minoxidil and risk of malignancy

• DermWorld Insights and Inquiries: Immune checkpoint inhibitor-induced lipodystrophy — Another affront to cancer

• FDA approves first oral option for dermatomyositis

• Does dupilumab improve height, bone density for children with atopic dermatitis?

• Mycosis fungoides with clinical features suggestive of seborrheic dermatitis

Aug. 26, 2026:

• Do collagen peptides affect skin aging?

• DermWorld What’s Hot: Saline for plantar warts

• Second-generation antihistamines in dermatology

• A treatment for dark circles?

• Impact of weight-loss interventions on psoriasis

Aug. 19, 2026:

• Potassium hydroxide vs. diclofenac for actinic keratosis

• DermWorld What’s Hot: Increase in tanning for Gen Z

• Tirzepatide-associated morbilliform drug eruption

• Energy-based devices for acne in skin of color

• Can graying hair improve with exosome therapy?

Aug. 12, 2026:

• Intralesional acyclovir vs. cryotherapy for plantar warts

• DermWorld What’s Hot: 5-FU/calcipotriol for AKs, keratinocyte carcinomas

• Is routine antihistamine use recommended for atopic dermatitis?

• Efficacy of conventional, biologic therapies in prurigo nodularis

• Do patients with HS or psoriasis have increased risk of cSCC?

Aug. 5, 2026:

• Spironolactone for female pattern hair loss in younger women

• DermWorld Insights and Inquiries: The likely Lilliputian meaning of eosinophils in psoriasis

• Topical therapies for melasma

• Risk factors for the development of acral melanoma

• Warning letter issued to manufacturer of acne, skin care products

July 29, 2026:

• Risk of cardiovascular disease in dermatology patients taking niacinamide

• DermWorld What’s Hot: A potential new therapy for dermatomyositis?

• Is extended dupilumab dosing as effective as standard dosing for AD?

• GLP-1 use and clinical outcomes in HS patients

• Emerging therapies for lichen simplex chronicus

July 22, 2026:

• Is there a role for topical skin care products with GLP-1 use?

• DermWorld What’s Hot: 2026 Allergen of the Year

• AAD seeks member comments for AD guidelines

• Omalizumab vs. dupilumab vs. remibrutinib for chronic spontaneous urticaria

• Does sirolimus have a protective role against nonmelanoma skin cancer?

July 15, 2026:

• Oral minoxidil: 2.5 mg vs. 5 mg for male androgenetic alopecia

• DermWorld What’s Hot: Use of compounded sterile preparations

• Malignancy risk with biologics vs. topical therapy for psoriasis

• A masquerade for stasis dermatitis of the lower extremities

• Are plastics in personal care products tied to skin disease?

July 8, 2026:

• Potassium monitoring in older females taking spironolactone

• DermWorld What’s Hot: Preoperative antibiotic prophylaxis and penicillin allergy

• Topical vs. systemic corticosteroids for DRESS syndrome

• Which JAK inhibitor shows greatest efficacy for alopecia areata?

• Psoriasis and risk of 26 cancers

July 1, 2026:

• Spironolactone for acne in females: Evidence and recommendations

• DermWorld Insights and Inquiries: Human papillomavirus 42 — Putting a finger on the pathogenesis of digital papillary adenocarcinomas

• Does caffeine affect hair growth?

• Ingredients for oral photoprotection

• FDA approves risankizumab for pediatric use in psoriatic disease

June 24, 2026:

• Skin care ingredients recommended by cosmetic dermatologists

• DermWorld What’s Hot: Fusion gene rearrangement in advanced melanoma

• Severe psoriasis relapse following tralokinumab for atopic dermatitis

• Is timolol gel effective in healing open surgical wounds?

• What factors contribute to incomplete excision of nonmelanoma, melanoma skin cancer?

June 17, 2026:

• Practical recommendations for seborrheic dermatitis: An expert consensus

• DermWorld What’s Hot: Rituximab and concurrent IVIG treatment

• What therapies show best long-term effectiveness for psoriasis?

• Long-term efficacy, safety of repeated onabotulinumtoxinA treatments

• Hidradenitis suppurativa may increase cancer risk

June 10, 2026:

• Suicidality reports in acne patients treated with isotretinoin, antidepressants

• Academy praises FDA for approving new sunscreen ingredient

• DermWorld What’s Hot: Treating isotretinoin-induced myalgias

• Ruxolitinib cream vs. triamcinolone cream for atopic dermatitis

• FDA issues warning letter to Revlon

• BD issues recall for ChloraPrep and FREPP applicators

June 3, 2026:

• Risk of cardiovascular events with 5-alpha-reductase inhibitors in androgenetic alopecia

• DermWorld Insights and Inquiries: A potential roadMAP for treating malignant atrophic papulosis

• Yellow nail syndrome: Diagnosis and management

• Gender-based cost disparities of topical minoxidil

• Delgocitinib for patients with frontal fibrosing alopecia

• FDA warns consumers about skin-lightening products containing mercury, hydroquinone

May 27, 2026:

• 5-fluorouracil and calcipotriene for actinic keratosis, keratinocyte carcinoma

• DermWorld What’s Hot: Imiquimod vs. radiotherapy for lentigo maligna

• Oral oxybutynin chloride, biologics for hidradenitis suppurativa

• Topical metformin vs. dapsone for acne

• Do AI scribes lead to improved efficiency in EHRs?

• FDA issues warning letters about skin care products containing mercury

May 20, 2026:

• Saline immersion for treating refractory plantar warts

• DermWorld What’s Hot: Botulinum toxin as treatment for vascular skin conditions

• Facial nodules following filler injections after starting tirzepatide

• FDA approves dupilumab for young children with uncontrolled chronic spontaneous urticaria

• 2024 preview period for doctors and clinicians is now open

• Nationwide recall of eczema cream

May 13, 2026:

• Beyond isotretinoin: Systemic therapies for acne

• DermWorld What’s Hot: Difamilast approval for pediatric AD patients

• UK recommends additional actions to minimize suicide risk from finasteride, dutasteride

• A review of exosome-based therapies in dermatology

• Share your experience with 2025 MIPS data submission

• 2026 QPP exception applications now available

May 6, 2026:

• Nutritional, light-based, and lifestyle interventions for androgenetic alopecia

• DermWorld Insights and Inquiries: Granular C3 dermatosis in granular detail

• Risk of infection with JAK inhibitors

• Oral vs. topical tranexamic acid for melasma

• Does a Mediterranean diet improve psoriasis severity?

• Topical pain relief drug, OTC sunscreen drugs violate Current Good Manufacturing Practice regulations

April 29, 2026:

• A timeline for increased hair shedding from topical minoxidil

• DermWorld What’s Hot: Basal cell nevus syndrome

• CMS updates Advance Beneficiary Notice (ABN) form: What practices need to know

• FDA approves dupilumab for children with chronic spontaneous urticaria

• Most effective treatments for atopic dermatitis?

• Cosmetic products marketed as gel nail polish remover contain prohibited ingredient

April 22, 2026:

• Spironolactone and oral minoxidil in women with alopecia

• DermWorld What’s Hot: Nicotinamide and nonmelanoma skin cancer

• Infliximab dosing intervals for hidradenitis suppurativa

• Weekly vs. daily bathing for people with atopic dermatitis

• Does immunosuppression impact cSCC outcomes?

• 2026 MIPS Value Pathways registration now open

April 15, 2026:

• Benefits, misconceptions, and risks of skin care supplements

• DermWorld What’s Hot: Using a RegiSCAR score to evaluate DRESS

• AAD seeks member comments for HS guidelines

• FDA approves dermal filler for treating wrinkles in décolleté area

• Local recurrence, survival in patients with melanoma in situ

April 8, 2026:

• Does oral spironolactone improve acne in women?

• DermWorld What’s Hot: mRNA COVID vaccine and immune checkpoint inhibitor response

• Herbal medicines for psoriasis

• Efficacy of PDT and fractional CO2 laser for onychomycosis

• Real-world effectiveness of JAK inhibitors in vitiligo

April 1, 2026:

• Aesthetic treatment considerations for perimenopausal, menopausal patients

• DermWorld Insights and Inquiries: Cocaine-associated plasma cell orificial mucositis — Anything goes

• Effects of PRP, minoxidil in patients with androgenetic alopecia

• Vaccination recommendations in patients with atopic dermatitis taking JAK inhibitors

• Dermatologic signs of eating disorders

March 25, 2026:

• Finasteride and dutasteride: Depression, suicidal ideation

• DermWorld What’s Hot: Need for expanded patch testing

• FDA approves icotrokinra for plaque psoriasis

• Cutaneous malignancy after biologic therapy

• Adverse events of topical rosacea treatments

March 18, 2026:

• Oral hyaluronic acid supplement: Does it improve skin aging?

• DermWorld What’s Hot: Insurance denial of ‘cosmetic’ conditions

• Is topical urea beneficial for onychomycosis?

• Does the application of emollients prevent pediatric eczema?

• Cannabidiol in dermatology

March 11, 2026:

• Does home-use low-level laser therapy improve androgenetic alopecia?

• DermWorld What’s Hot: Is an oral IL-23 inhibitor on the way for psoriasis?

• Safety of the use of concomitant GLP-1 and biologic therapy

• TNF-alpha inhibitor therapy for granuloma annulare

• Do patients understand skin cancer-related terminology?

March 4, 2026:

• Flutamide for hair loss

• DermWorld Insights and Inquiries: Eosinophilic pustular folliculitis — Six decades of progress

• A novel application of punch excision therapy for keloids

• Migraine and rosacea: Is there a connection?

• Dermatologic safety of cosmetic products marketed to children

Feb. 25, 2026:

• Acne relapse after isotretinoin treatment

• DermWorld What’s Hot: cSCC and adjuvant radiation therapy

• Where to inject botulinum toxin for ‘bunny lines’

• Predictors of drug survival of biologics in HS

• Utilization of patch testing for contact dermatitis: Insights from DataDerm™

Feb. 18, 2026:

• Oral finasteride and sexual adverse events

• DermWorld What’s Hot: Distinguishing persistent nevi from melanoma on histopathology

• Derm Coding Consult: Coding for surface radiation therapy in dermatology — Practical guide

• New study outlines safe preparation of buffered lidocaine

• Cardiovascular, thromboembolic risks of JAK inhibitors in atopic dermatitis

Feb. 11, 2026:

• Excision vs. topical 5-FU and photodynamic therapy in Bowen’s disease

• DermWorld What’s Hot: Sunscreen doping

• Surgical interventions for hidradenitis suppurativa

• Is dual biologic therapy effective?

• Do patients understand skin cancer-related terminology?

Feb. 4, 2026:

• Safety of oral minoxidil in pediatric patients

• DermWorld Insights and Inquiries: Deeper thoughts about acne keloidalis nuchae

• Perioperative strategies for advanced melanoma, nonmelanoma skin cancers

• Characteristics of super-responders in patients with alopecia areata treated with tofacitinib

• Hidden UV filters in 150 popular sunscreens

• Joint Commission, National Quality Forum to align patient safety event lists

Jan. 28, 2026:

• Topical estrogens for skin aging

• DermWorld What’s Hot: Driver of psoriatic itch

• Outcomes across JAK inhibitors in prurigo nodularis

• Anticholinergic treatments for hyperhidrosis

• Assessment of GPT-4 vision in dermoscopic image analysis

Jan. 21, 2026:

• Does finasteride lead to depression, suicide?

• DermWorld What’s Hot: A tool to modernize, personalize biologic dosing for psoriasis

• Misdiagnoses of hair, scalp disorders in patients with skin of color

• The molecular effects of indoor tanning

• Resistance to biologic therapy in psoriasis

Jan. 14, 2026:

• Are light-based therapies effective for hair loss?

• DermWorld What’s hot: Local recurrence and survival in patients with melanoma in situ

• Strategies to reduce the risk of surgical site infections of the skin

• Refractory vulvar lichen sclerosus

• Effects of PRP on androgenetic alopecia alone or with minoxidil

Jan. 7, 2026:

• Is beef tallow effective for dermatologic conditions?

• DermWorld Insights and Inquiries: Cannabis arteritis — Getting higher on the differential diagnosis list of ulcerative lesions

• GLP-1s in the adjunctive treatment of patients with HS

• Efficacy of botulinum toxin A for melasma?

• CMS opens data submission for 2025 MIPS performance year

Dec. 17, 2025:

• Antiandrogen therapy for female pattern hair loss

• DermWorld Insights and Inquiries: Long COVID has a lot of nerve

• Hidradenitis suppurativa treatment during pregnancy, lactation

• The role of magnesium in dermatology

• A digital photography guide for dermatologists

Dec. 10, 2025:

• Hydrocolloid dressing vs. petroleum for scar appearance after dermatologic surgery

• DermWorld Insights and Inquiries: The illusions of IgG4-related skin disease

• Recovering from SJS and TEN

• Vitamin D and rosacea: Is there a link?

• Psoriasis therapy on social media

Dec. 3, 2025:

• GLP-1s and telogen effluvium

• DermWorld Insights and Inquiries: Pityriasis rosea and pityriasis rosea-like eruptions — A Christmas tale

• Combination oral minoxidil and baricitinib for alopecia areata

• OIG report supports dermatologists’ use of modifier 25, CMS requires no further regulations

• FDA sends warning letter to DermRite Industries, LLC

• Understanding your MIPS cost reports

Nov. 19, 2025:

• Benefits and harms of 42 chronic urticaria interventions

• DermWorld Insights and Inquiries: The aryl hydrocarbon receptor — Tapinarof is taking off

• Switching biologics in patients with psoriasis

• Dermoscopic changes in acquired melanocytic nevi during and after pregnancy

• 2026 Medicare Physician Fee Schedule: Dermatology impact tables available

Nov. 12, 2025:

• Efficacy of OTC androgenetic alopecia therapies vs. FDA-approved monotherapies

• DermWorld Insights and Inquiries: JAK inhibitors battle in the heavyweight class

• Is there increased psoriasis risk in patients taking dupilumab for atopic dermatitis?

• Efficacy of medical interventions for moderate-to-severe hidradenitis suppurativa

• FDA warns companies over illegal marketing of botulinum toxin products

• Members report difficulty obtaining Kenalog

Nov. 5, 2025:

• An OTC finasteride alternative?

• DermWorld Insights and Inquiries: Diagnosing the primary cutaneous SMARCA4 deficient cutaneous tumor — You don’t know what you got ‘til it’s gone

• Location of body itch and stress in patients with chronic pruritus

• Are hormonal intrauterine devices linked to melasma?

• Medicare finalizes slight payment increase for 2026

Oct. 29, 2025:

• Does nicotinamide supplementation prevent skin cancer?

• DermWorld Insights and Inquiries: The 2025 Allergen of the Year is to dye for

• GLP-1 receptor agonists and isotretinoin

• Adalimumab vs. adalimumab with methotrexate for psoriasis

• FDA issues warning letter to Naturich Cosmetique Labs

Oct. 22, 2025:

• Do dutasteride and finasteride increase mood disorder risk in men with androgenetic alopecia?

• DermWorld Insights and Inquiries: A potentially effective itsy-bitsy therapy for spider angiomas — Topical timolol

• Warren R. Heymann, MD, FAAD, selected as DermWorld physician editor

• Academy mourns the passing of Eugene Joseph Van Scott, MD

• CMS reverses decision to hold Medicare payments

• FDA warns of potential risks with radiofrequency microneedling

• 2024 MIPS final scores now available, Targeted Review request deadline Nov. 14

Oct. 15:

• Do new psoriasis biologics have better safety profiles than adalimumab?

• DermWorld Insights and Inquiries: Erectile dysfunction in dermatology — A silent epidemic

• AAD seeks member comments for pediatric AD guidelines

• FDA approves cemiplimab for adjuvant treatment of cutaneous squamous cell carcinoma

• Melanoma rates after in vitro fertilization

Oct. 8, 2025:

• KOH vs. diclofenac for the treatment of actinic keratosis

• DermWorld Insights and Inquiries: Injecting ideas (and therapies) in digital mucous cysts

• FDA approves remibrutinib for chronic spontaneous urticaria

• Antidepressant usage and postoperative outcomes on basal cell carcinomas

• Does hormone therapy increase risk of psoriasis?

Oct. 1, 2025:

• Antiandrogen therapy for the treatment of female pattern hair loss

• DermWorld Insights and Inquiries: Lupus miliaris disseminatus faciei — A Simon and Garfunkel playlist

• Academy mourns the passing of Neil Swanson, MD

• Academy mourns the passing of Franklin Pass, MD

• How effective are monotherapies for hidradenitis suppurativa?

Sept. 24, 2025:

• Is red light PDT with ALA effective for the treatment of BCC?

• DermWorld Insights and Inquiries: The 21st Century Cures Act — What a difference a day makes

• Longitudinal melanonychia: Benign or malignant?

• FDA approves ruxolitinib cream for pediatric AD

• Off-label use of biologics, JAK inhibitors for scarring alopecias

Sept. 17, 2025:

• Is there an association between isotretinoin and sexual dysfunction?

• DermWorld Insights and Inquiries: Exploring the gamut of monoclonal gammopathy of cutaneous significance

• Is there an association between food allergies and atopic dermatitis?

• Pediatric skin care regimens on TikTok

• Antifungal resistance of the T. mentagrophytes/T. interdigitale species complex

Sept. 10, 2025:

• Most effective monotherapy for androgenetic alopecia

• DermWorld Insights and Inquiries: Twenty-first century pellagra

• Is there an association between JAKis and malignancy risk in alopecia areata?

• PRP with fractional laser for vitiligo

• Who’s using cosmetic lasers in the U.S.?

Sept. 3, 2025:

• Comparison of botulinum toxin A formulations for treating glabellar strain

• DermWorld Insights and Inquiries: Trichobacteriosis — A salute to the Shelleys

• Academy mourns the passing of Richard Scher, MD

• AAD seeks member comments for AD diagnostic testing guidelines

• Is hypochlorous acid beneficial for inflammatory skin conditions?

• How do patients want physicians to dress?

Aug. 27, 2025:

• A tool to assess patients at high-risk for cutaneous squamous cell carcinoma

• DermWorld Insights and Inquiries: Chanarin-Dorfman syndrome — Shifting out of neutral

• Carbon dioxide laser and triamcinolone acetonide for keloid and hypertrophic scar treatment

• Azathioprine for severe alopecia areata

• Derm Coding Consult: More carriers implementing E/M code level reviews

Aug. 20, 2025:

• Oral vs. topical finasteride: Sexual, neuropsychiatric AEs

• DermWorld Insights and Inquiries: Sweating over sweat gland carcinomas: Part 2 — Eccrine mucin-producing sweat gland carcinoma

• Are topical corticosteroids associated with increased risk of pregnancy complications in psoriasis patients?

• Efficacy of PRP for melasma: Microneedling vs. microinjections

• Cancer mortality risk for firefighters

Aug. 13, 2025:

• Effects of GLP-1RA on inflammatory skin diseases

• DermWorld Insights and Inquiries: Sweating over sweat gland carcinomas: Part 1 — Squamoid eccrine ductal carcinoma

• Beta-HPV virus can cause cutaneous squamous cell carcinoma

• DIY cosmetic neuromodulator injection tutorials on YouTube

• MCC survival rates increased following immunotherapy approval

• Voluntary recall of antiseptic soaps, external analgesics

Aug. 6, 2025:

• Minoxidil, finasteride, dutasteride monotherapy for male pattern hair loss

• DermWorld Insights and Inquiries: Further dermatologic observations in cystic fibrosis

• DermWorld Insights and Inquiries — Another Viewpoint: The squeeze of the FBSEs: An academic department perspective

• A review of dupilumab and alopecia areata

• Early termination of adjuvant immunotherapy in melanoma

• CMS announces MIPS EUC policy for clinicians following Texas severe storms

July 30, 2025:

• Intralesional acyclovir vs. quadrivalent HPV vaccine for recalcitrant warts

• DermWorld Insights and Inquiries: PRIDE without prejudice

• FDA approves delgocitinib for chronic hand eczema

• Efficacy of hedgehog inhibitors for advanced basal cell carcinoma

• 2025 APM incentive payments now available — Action may be needed

July 23, 2025:

• How to recognize a difficult squamous cell carcinoma

• DermWorld Insights and Inquiries: Sebaceous carcinoma — Double trouble

• Exploring novel therapies for acne scar treatment

• Survival after cessation of immunotherapies in melanoma

• Radiofrequency microneedling for hyperhidrosis

• Voluntary recall of cefazolin for injection due to mislabeling

July 16, 2025:

• Female pattern hair loss: Is systemic minoxidil effective over the long term?

• DermWorld Insights and Inquiries: Pathway to clarity — The new and improved Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis (MPATH-Dx) version 2.0

• Medicare payment rate to rise more than 3% in 2026

• Progression of basal cell carcinomas in patients awaiting surgical intervention

• Comparing monotherapies for alopecia areata

• Completed suicide in patients with skin disease

July 9, 2025:

• Do at-home LED devices for acne work?

• DermWorld Insights and Inquiries: Standard postoperative wound care practice may be all wet

• Academy mourns the passing of Ronald L. Moy, MD

• Academy mourns the passing of Frederick F. Castrow II, MD

• Rates of dissatisfaction with hidradenitis suppurativa treatments

• Adalimumab vs. biosimilars for psoriasis

July 2, 2025:

• Isotretinoin for seborrheic dermatitis

• DermWorld Insights and Inquiries: Turning our attention to melanoma risk in Turner syndrome

• CMS updates MUE limit for Ameluz — Effective July 1, 2025

• Safety of JAK inhibitors in pregnancy, lactation

• Ruxolitinib vs. roflumilast for atopic dermatitis

• CMS releases 2024 Open Payments data

June 25, 2025:

• Safety of low-dose oral minoxidil in older patients

• DermWorld Insights and Inquiries: Metastatic uveal melanoma — Tebentafusp unobfuscated

• New focused atopic dermatitis guidelines update available

• FDA approves dupilumab to treat patients with bullous pemphigoid

June 18, 2025:

• Incidence of keratinocyte carcinoma with use of acitretin

• DermWorld Insights and Inquiries: Beef tallow for eczema — Grade A prime or just another bum steer?

• Academy mourns the passing of Paul S. Russell Jr., MD, FAAD

• Low-level laser, LED therapy for alopecia

• Is dermatologic surgery safe, effective for older patients?

• Is upadacitinib cardioprotective in chronic inflammatory diseases?

June 11, 2025:

• Combination oral minoxidil and bicalutamide for the treatment of female pattern hair loss in adolescents

• DermWorld Insights and Inquiries: From Down Under to all over — Kava-induced cutaneous adverse reactions

• Derm Coding Consult: Appropriate use of skin substitutes in dermatology — Documentation and coding guidance

• Marta J. Van Beek, MD, MPH, FAAD, elected to AMA Board of Trustees

• Contact allergens in top-selling diaper preparations

• 2023 QPP participation and performance data now available

June 4, 2025:

• Are nail products safe?

• DermWorld Insights and Inquiries: High-dose vitamin D may be a ray of sunshine for treating sunburn

• Fatty acid supplements and atopic dermatitis?

• Low-level laser, LED therapy for alopecia

• More physicians moving to hospital-owned practices, private equity groups

• 2023 QPP Preview Period is now open

May 28, 2025:

• Efficacy of combination topical finasteride and minoxidil in male androgenetic alopecia

• DermWorld Insights and Inquiries: Loss and legacy — A tribute to Robert F. Duffy, MD

• FDA approves roflumilast foam for scalp, body psoriasis

• Excision specimens show residual basal cell carcinoma

• AADA advocating on CLIA lab director requirements

• Advocacy win: Indoor tanning tax safe from repeal

May 21, 2025:

• Factors associated with relapse after isotretinoin treatment

• DermWorld Insights and Inquiries: Fixating on doxycycline-induced fixed drug eruptions

• Can tattoos increase risk of skin cancer?

• Methotrexate gel in combination with microneedling vs. cryotherapy for the treatment of cutaneous warts

• Off-label use of upadacitinib in dermatology

• AADA offers support for CLIA lab director application issues

May 14, 2025:

• What factors may contribute to premature hair graying?

• DermWorld Insights and Inquiries: The malignant risk in circumscribed palmar or plantar hypokeratosis — Summoning Charles Dickens and Freddie Mercury

• Isotretinoin lab monitoring for acne patients

• Tirbanibulin for AK in clinical practice

• FDA alert for contaminated tattoo ink products

• CMS suspends eight Improvement Activities for 2025

May 7, 2025:

• Low-dose oral minoxidil vs. combination therapy with dutasteride or finasteride

• DermWorld Insights and Inquiries: Getting a head up on cutaneous scalp malignancies

• Academy mourns the passing of Richard B. Odom, MD, FAAD

• Considerations when choosing fillers

• DataDerm™: 2024 Annual Report

• Sunscreen safety, dispelling myths

April 30, 2025:

• Efficacy of spironolactone in treating patients with acne

• DermWorld Insights and Inquiries: A tale of two disorders of hypopigmentation — The potential role of Cutibacterium acnes dysbiosis in progressive macular hypomelanosis and lichen striatus

• Is the severity of shedding from topical minoxidil linked to treatment efficacy?

• Can immune checkpoint inhibitors reduce actinic keratoses?

• Pharmaceutical company issues recall of anesthetic

• Open Payments review period

April 23, 2025:

• Recommendations for the use of topical, oral minoxidil

• DermWorld Insights and Inquiries: Adding protothecosis to the protocol

• FDA approves dupilumab for chronic spontaneous urticaria

• Long-term effectiveness of adalimumab for the treatment of hidradenitis suppurativa

• FDA alert for compounded topical finasteride products

• FDA alert for cosmetic products

April 16, 2025:

• Is isotretinoin linked to psychiatric events for acne patients?

• DermWorld Insights and Inquiries: The not-so-full body skin examination

• What every dermatologist should know about measles

• Is there a risk of major cardiovascular events following nicotinamide exposure?

• Fractional CO2 laser for early treatment of surgical scars

April 9, 2025:

• Finasteride: Risk of depression and suicide?

• DermWorld Insights and Inquiries: Till death do us part — Love, marriage, and cutaneous oncology

• Adding oral minoxidil to standard treatment for lichen planopilaris

• UV/LED nail lamp radiation exposure during manicures, pedicures

• Risk of malignancy in patients treated with TNF-α inhibitors

• Telehealth flexibilities extended through September

April 2, 2025:

• Oral vs. topical minoxidil in patients with androgenetic alopecia

• DermWorld Insights and Inquiries: Becoming ‘sensitized’ to the clinical utility of the term “urticarial dermatitis” (a subtype of the dermal hypersensitivity reaction pattern)

• Efficacy of hyperpigmentation treatments

• Upadacitinib vs. dupilumab for atopic dermatitis

• Spironolactone: Quality, reliability of TikTok videos

March 26, 2025:

• What’s the best way to dissolve fillers with hyaluronidase?

• DermWorld Insights and Inquiries: Propranolol for infantile hemangiomas — Start to finish

• 2025 Allergen of the Year

• Herbal remedies for melasma

• Nearly 20% of adult eczema patients have multiple eczema conditions

March 19, 2025:

• Association between actinic keratosis treatments and use of antihypertensives?

• DermWorld Insights and Inquiries: Mastering dermatology

• Laser and energy treatments for acne scarring

• Efficacy of upadacitinib vs. dupilumab for atopic dermatitis

• 2025 U.S. measles cases surpass 2024 total

• FDA testing confirms minimal benzene in most benzoyl peroxide acne products, some voluntary recalls issued

• FDA issues warning letters for unapproved sunscreens

March 12: 2025:

• GLP-1RA medications and hair loss

• DermWorld Insights and Inquiries: Antihypertensive agents and eczema — New data for older patients

• Combined oral contraceptives may be beneficial for HS

• Probiotic supplementation with doxycycline for moderate acne

• The ethics of paper mills and payment for authorship

March 5, 2025:

• Is there a link between oral minoxidil and pericardial effusion?

• DermWorld Insights and Inquiries: Giving a NOD2 to Yao syndrome

• Higher cumulative dose of isotretinoin tied to lower acne relapse rate

• Roflumilast cream for AD in adults, children

• AI-enabled hand sensor may reduce nocturnal scratching

Feb. 26, 2025:

• 5-FU in patients with squamous cell carcinoma in situ

• DermWorld Insights and Inquiries: Living with trimethylaminuria — Research awaiting the smell of success

• Do topical corticosteroids increase risk of pregnancy complications?

• High rates of potentially unnecessary topical antifungal prescribing

• FDA issues warning letter concerning Dermo-Jet Needleless Injector

Feb. 19, 2025:

• Red and green LED light therapy in individuals with androgenetic alopecia

• DermWorld Insights and Inquiries: Living with trimethylaminuria — Research awaiting the smell of success

• Safety of using JAK inhibitors in elderly patients with atopic dermatitis

• Allergic contact cheilitis from beverages, food

• Wound characteristics among patients exposed to xylazine

Feb. 12, 2025:

• Is there an association between metformin use and the risk of nonmelanoma skin cancer?

• DermWorld Insights and Inquiries: Making a pitch for the C-reactive protein/albumin ratio

• Suicidal behaviors among patients with psoriasis treated with biologics

• Long-term effectiveness, reasons for discontinuation of dupilumab in atopic dermatitis

• Occupational contact dermatitis among firefighters

• CMS announces automatic MIPS exception for California wildfires

Feb. 5, 2025:

• PRP, microneedling, and topical minoxidil for refractory severe androgenetic alopecia

• DermWorld Insights and Inquiries: Clinical and therapeutic judgment regarding confluent and reticulated papillomatosis of Gougerot and Carteaud

• Act now to stop Medicare payment cuts and provide an inflationary update

• Semaglutide in patients with hidradenitis suppurativa

• Adverse events associated with JAK inhibitors among dermatology patients

• Targeted alkali thermolysis patch for patients with primary axillary hyperhidrosis

• AAD seeks member comments for AD guidelines

Jan. 29, 2025:

• Female pattern hair loss: Topical 17α-ethinyl estradiol with minoxidil vs. topical minoxidil

• DermWorld Insights and Inquiries: Necrotizing infundibular crystalline folliculitis — Not yet crystal clear

• Treatment with intralesional 5-FU in patients with keloids

• Diagnosing and managing DRESS

• Deadline approaching to comment on USP draft buffered lidocaine monograph

Jan. 22, 2025:

• Considerations regarding GLP-1 receptor agonist use in dermatology

• DermWorld Insights and Inquiries: An encapsulation of palisaded encapsulated neuromas

• Pregabalin vs. gabapentin in patients with chronic pruritus

• Oral tranexamic acid for treatment of post-inflammatory hyperpigmentation

• Local recurrence, metastasis, and mortality among patients with thin, in situ melanomas

Jan. 15, 2025:

• Tretinoin vs. other topical therapies for photoaging

• DermWorld Insights and Inquiries: Dupilumab treatment of bullous pemphigoid — Hoping for approval on the double

• DermWorld Coding Consult: What to know about coding dermatology encounters after the Public Health Emergency (PHE) and beyond

• Treatment with low-dose naltrexone in patients with lichen planus of the nails

• CGRP inhibitors may reduce acne, rosacea rates

• AADA educates employers on impact of skin conditions

• AAD offers disaster relief loans to members affected by Los Angeles wildfires

Jan. 8, 2025:

• Topical finasteride with minoxidil vs. topical minoxidil alone for male-pattern androgenic alopecia

• DermWorld Insights and Inquiries: The treatment of systemic juvenile xanthogranulomas matures

• Academy mourns the passing of Marianne O'Donoghue, MD, FAAD

• Weight-loss drugs for managing patients with HS

• Atenolol vs. propranolol for the treatment of infantile hemangioma

• CMS opens data submission for 2024 MIPS performance year

• Telehealth flexibilities extended until March 31: Geographic and location waivers

Dec. 18, 2024:

• Combined topical 5-FU and calcipotriene for superficial keratinocyte carcinomas

• DermWorld Insights and Inquiries: Holiday greeting 2025

• Upadacitinib vs. dupilumab for atopic dermatitis

• Doxycycline for patients with central centrifugal cicatricial alopecia

• Association between access to tanning bed facilities and melanoma?

• 2025 telehealth flexibilities and policy updates

Dec. 11, 2024:

• Consensus guidelines for off-label use of oral minoxidil for hair loss

• DermWorld Insights and Inquiries: Idiopathic granulomatous mastitis joins the pantheon of erythema nodosum-associated disorders

• Diagnostic delays, mortality among patients with calciphylaxis

• Trends in patch-test positivity to methylchloroisothiazolinone and methylisothiazolinone

• Mpox update: Recommendations for clinicians

Dec. 4, 2024:

• What’s the best treatment for squamous cell carcinoma in situ?

• DermWorld Insights and Inquiries: Darier disease is rough clinically and therapeutically. MEK inhibition may offer a smoother future.

• Oral tranexamic acid as an adjuvant therapy for melasma

• Managing dupilumab-related ocular surface disorders in patients with AD

• Topical metformin for the treatment of CCCA

Nov. 20, 2024:

• Is there an association between treatment with retinoids and sexual dysfunction?

• DermWorld Insights and Inquiries: Topical isotretinoin for ichthyoses: Striving for an ‘A’ grade

• FDA approves rosacea treatment

• Efficacy of intralesional vitamin D3 vs. triamcinolone in patients with keloids

• Predictive factors for long-term high response to upadacitinib in patients with AD

Nov. 13, 2024:

• Risk of pericardial effusions in patients with alopecia on low-dose oral minoxidil

• DermWorld Insights and Inquiries: The latest dirt on terra firma-forme dermatosis

• Rate of residual BCC among excision specimens after shave biopsy

• Association of topical corticosteroid use during pregnancy with stillbirth, cesarean delivery in women with psoriasis

• Atopic march risk in pediatric patients with atopic dermatitis taking dupilumab vs. other immunomodulators

• CMS announces MIPS EUC policy for clinicians affected by hurricanes Milton, Helene, and Francine

Nov. 6, 2024:

• Do UV nail lamps increase cancer risk?

• DermWorld Insights and Inquiries: Lipoid proteinosis’ weak, hoarse cry is crying for targeted therapeutic intervention

• FDA warns against use or purchase of Skin-Cap aerosol spray products

• Adverse events among pediatric patients treated with JAK inhibitors

• Efficacy and tolerability of a 2.6% benzoyl peroxide cleanser in patients with acne and sensitive skin

• Emerging fungal infection spread via sexual contact

Oct. 20, 2024:

• Breast health outcomes in women on oral 5-alpha reductase inhibitors

• DermWorld Insights and Inquiries: The breathless complications of anti-MDA-5-positive dermatomyositis

• What symptoms are most significantly associated with melanoma recurrence?

• Omega-3 fatty acids for isotretinoin-induced cheilitis

• Laser hair removal in patients with hidradenitis suppurativa

Oct. 23, 2024:

• Botulinum toxin type A with topical minoxidil vs. topical minoxidil alone in males with androgenetic alopecia

• DermWorld Insights and Inquiries: Shocking news — Heat shock protein inhibition finally enters the realm of dermatologic therapy

• Topical ivermectin vs. metronidazole in patients with rhinophyma

• Abrocitinib in patients with prurigo nodularis, chronic pruritus of unknown origin

• Supplemental patch testing identified allergens missed by standard screening series

Oct. 16, 2024:

• High levels of benzene detected in OTC acne treatments

• DermWorld Insights and Inquiries: Homing in on hornerin — Breaking down the barrier to understand its crucial role in atopic dermatitis

• Safety of treatment with IL-4/IL-13 inhibitors vs. JAK inhibitors in patients with AD

• Artificial intelligence in melanoma and keratinocyte carcinoma diagnosis

• Stigmas about mental health care remain for physicians, residents

Oct. 9, 2024:

• Topical 5-FU/calcipotriene cream for the treatment of squamous cell carcinoma in situ

• DermWorld Insights and Inquiries: Shedding light on tumoral melanosis

• FDA weighing approval of new sunscreen ingredient

• Which treatments reduce inflammatory lesion counts in patients with rosacea?

• Efficacy of secukinumab in patients with lichen planus

Oct. 2, 2024:

• Risk of IBD in patients receiving isotretinoin

• DermWorld Insights and Inquiries: The pregnant pause in cutaneous lymphoma

• Hydroxychloroquine in patients with lichen sclerosus

• Abrocitinib vs. dupilumab drug survival for atopic dermatitis

• PRAME immunohistochemistry in differentiating melanoma in situ and dysplastic nevus in non-acral nevus–associated melanoma in situ

• AADA Medicare physician payment podcast available

• 2023 targeted review request deadline approaching

Sept. 25, 2024:

• Cyclosporine vs. dupilumab vs. methotrexate for patients with AD

• DermWorld Insights and Inquiries: The expanding horizon of anti-IL-36 therapy

• FDA approves new treatment for immune-mediated vasculitis

• Factors associated with residual tumor at time of Mohs micrographic surgery for BCC, SCC

• Risankizumab’s long-term efficacy for psoriasis

• MIPS EUC reweighting requests deadline extended due to Change Healthcare cyberattack

Sept. 18, 2024:

• Spironolactone for alopecia: Blood pressure changes

• DermWorld Insights and Inquiries: The appropriate dermatologic response when considering the capillary malformation-arteriovenous malformation syndrome — Fast flow to referral

• FDA approves lebrikizumab for moderate-to-severe atopic dermatitis

• Management of scabies in children weighing less than 15 kg, pregnant or breastfeeding women

• Assessing supervision, complication-reporting in medical spas

Sept. 11, 2024:

• Safety of low-dose oral minoxidil for hair loss in patients receiving antihypertensive medications

• DermWorld Insights and Inquiries: Atopic dermatitis hide and seek — The impending role of OX40 inhibition

• Risk, timing of isotretinoin-related abnormalities on lab tests

• Risk of invasive fungal infections in patients receiving biologic

• Treating post-inflammatory hyperpigmentation in patients with skin of color

Sept. 4, 2024:

• Most effective treatment for moderate-to-severe acne

• DermWorld Insights and Inquiries: Periocular hypopigmentation of the elderly — A new POTUS dermatosis?

• Berdazimer gel in patients with molluscum contagiousum

• Lasers for the treatment of nail psoriasis

• JAK inhibitors for alopecia areata: Dermatologist knowledge, attitudes

Aug. 28, 2024:

• Is the oral contraceptive pill associated with frontal fibrosing alopecia?

• DermWorld Insights and Inquiries: Advances in therapy for the Cronkhite-Canada syndrome have increased survival — And that’s the way it is

• Academy mourns passing of James Alastair Carruthers,MD, FAAD, FRCPC

• Excision margins for optimal cure rates of melanoma in situ on the head, neck

• U.S. judge strikes down ban on worker ‘noncompete’ agreements

• MIPS EUC policy for Florida clinicians

Aug. 21, 2024:

• Botulinum toxin in males with androgenetic alopecia

• DermWorld Insights and Inquiries: AESOP — The ants and the grasshopper

• FDA approves nemolizumab for prurigo nodularis

• 2025 Medicare physician fee schedule proposed rule analysis

• JAK inhibitor prescribing trends for alopecia areata

• Medicare reveals negotiated drug prices for dermatology drugs

Aug. 14, 2024:

• Potassium monitoring among female acne patients treated with spironolactone

• DermWorld Insights and Inquiries: Taking a hard look at eosinophilic fasciitis on its golden anniversary

• Allergic contact dermatitis in patients with lichen planopilaris, frontal fibrosing alopecia

• Laser and light-based therapies for hirsutism in patients with PCOS

• Now available: 2023 MIPS performance feedback, targeted review request

• MIPS EUC policy for Texas clinicians

Aug. 7, 2024:

• Is oral minoxidil safe for pediatric patients?

• DermWorld Insights and Inquiries: Rounds on pityriasis rotunda

• Contact allergens in ‘clean’ children’s products

• Is cumulative methotrexate associated with liver fibrosis in patients with a history of moderate-to-severe psoriasis?

• DataDerm™: 2023 Annual Report

July 31, 2024:

• Does an increase in omega-3 fatty acids improve acne?

• DermWorld Insights and Inquiries: Which treatment modality of pyogenic granuloma is worth its weight in salt?

• Is there an association between HS and risk of venous thromboembolism?

• FDA approves third JAK inhibitor for alopecia areata

• Efficacy of tirbanibulin in treatment of actinic keratoses

July 24, 2024:

• Is there an association between benzoyl peroxide use and increased blood benzene levels?

• DermWorld Insights and Inquiries: Pancreatic panniculitis — Getting spooked by ghost cells

• AADA President visits Washington to advocate for Medicare physician payment reform, skin cancer checks

• Is there an association between PD-1 and PD-L1 inhibitors and keratoacanthoma and cSCC?

• CMS released 2025 Medicare Physician Fee Schedule Proposed Rule; AADA impact tables available

• Dapsone gel for acne vulgaris in patients with skin of color

July 17, 2024:

• Risk of breast, gynecologic malignancies in women using spironolactone for dermatologic conditions?

• DermWorld Insights and Inquiries: Reassuring patients with sclerosing lymphangitis of the penis that they will not get shafted

• FDA approves roflumilast cream for atopic dermatitis

• Neoadjuvant nivolumab and ipilimumab for resectable stage III melanoma

• Virtual scribes and physician time spent on EHRs

July 10, 2024:

• Efficacy of probiotics in the treatment of patients with acne

• DermWorld Insights and Inquiries: Vasculitis on the run

• Cosmetic tattoos, permanent makeup may cause allergic contact dermatitis

• Alaskapox infection: What dermatologists need to know

• Perioperative, intraoperative considerations for older patients undergoing dermatologic surgery

July 3, 2024:

• Tazarotene vs. imiquimod in patients with plane warts

• DermWorld Insights and Inquiries: Fire ant stings: From pain to gain — The therapeutic potential of solenopsin

• Efficacy of treatment with botulinum toxin in patients with rosacea

• Consensus guidelines for the use of methotrexate in patients with inflammatory skin disease

• Vaccination recommendations for adults with psoriasis, psoriatic arthritis

• 2023 MIPS final score preview now available

June 26, 2024:

• Finasteride vs. minoxidil for female pattern hair loss

• DermWorld Insights and Inquiries: Pathway to reducing medical errors

• Cutaneous drug reactions to psychedelics and hallucinogens

• Trichophyton indotineae: Clinical course, antifungal susceptibility, and genomic sequencing

• Is there an association between PD-1 and PD-L1 inhibitors and keratoacanthoma and cSCC?

June 19, 2024:

• Neuropsychiatric diagnoses after isotretinoin initiation in pediatric acne patients

• DermWorld Insights and Inquiries: Advances in pruritus therapeutics — It’s Greek to us

• Efficacy of treatment options for striae

• Sunscreen foundation recall due to microbial contamination

• Dermoscopic features associated with nail psoriasis

June 12, 2024:

• Acne in pregnancy: The safest options

• DermWorld Insights and Inquiries: CXCR4 antagonist therapy based on a WHIM syndrome

• Nonsteroidal approaches for treating patients with atopic dermatitis

• Social media tied to increased interest in cosmetic procedures

• First case of sexually transmitted fungal infection found in U.S.

• Pediatric Specialty Loan Repayment Program deadline approaching

June 5, 2024:

• Oral minoxidil vs. topical minoxidil for male androgenetic alopecia

• DermWorld Insights and Inquiries: Nailing the diagnosis of the BAP1 tumor predisposition syndrome

• Clotrimazole-betamethasone dipropionate for nonfungal skin conditions

• Oral melatonin in patients with recalcitrant melasma

• Reddit analysis reveals JAK inhibitor questions among AD patients

May 29, 2024:

• Isotretinoin plus desloratadine vs. isotretinoin alone in patients with acne

• DermWorld Insights and Inquiries: Reflections on infantile perianal pyramidal protrusion and Hippocrates

• AADA president delivers powerful testimony at congressional hearing on Medicare payment reform

• What effect does botulinum toxin have on cutaneous flushing?

• Live attenuated vaccines in children with AD treated with dupilumab

May 22, 2024:

• Dermatologic findings associated with semaglutide use

• DermWorld Insights and Inquiries: Striving to avoid an amebic nightmare — Recognizing cutaneous Balamuthia mandrillaris infection

• Characteristics and treatment of nail psoriasis

• Clinical features of pediatric longitudinal melanonychia

• What do dermatologists think about biosimilars?

May 15, 2024:

• Sexual dysfunction with 5-alpha reductase inhibitors for androgenetic alopecia

• DermWorld Insights and Inquiries: Acne necrotica — A real head-scratcher

• Benzoyl peroxide in acne: Risk of acute myeloid leukemia?

• Short contact lidocaine-prilocaine vs. lidocaine-tetracaine for cutaneous pain relief

• Benefits and harmful effects of treating patients with AD

• 2024 QPP exception applications are now available

May 8, 2024:

• A review of topical treatments for AK field therapy

• DermWorld Insights and Inquiries: Hard questions about subcutaneous fat necrosis of the newborn and hypercalcemia

• Derm Coding Consult: Reporting excimer laser therapy: When to use 96999 vs 9692x

• FTC narrowly passes final rule prohibiting non-compete clauses

• Low-dose isotretinoin for rosacea

• AAD Board selects Sabra Sullivan, MD, PhD, FAAD, as next Assistant Secretary Treasurer

May 1, 2024:

• Consensus statements for the treatment of vitiligo in younger patients

• DermWorld Insights and Inquiries: Eyebrow-raising complications of microblading

• Role of low-dose oral minoxidil for treatment of alopecia areata

• FTC votes to ban noncompete agreements for most workers

• Is acitretin effective for skin cancer prevention?

April 24, 2024:

• False negatives: How biotin can interfere with lab tests

• DermWorld Insights and Inquiries: Dermatofibrosarcoma protuberans recurrence — Size matters

• Risk of paradoxical eczema in patients receiving biologics for psoriasis

• Cardiovascular complications in derm patients receiving JAK-STAT inhibitors

• Dermatology mobile apps with AI features

April 17, 2024:

• Does low-dose oral minoxidil improve short anagen syndrome?

• DermWorld Insights and Inquiries: Weighing in on glucagon-like peptide-1 receptor agonists in dermatology

• CDC investigates counterfeit Botox, AADA seizes opportunity

• Evaluating SCC: Reflectance confocal microscopy and optical coherence tomography

• A tool to improve communication with patients with hidradenitis suppurativa

April 10, 2024:

• Whey protein consumption and acne severity in men with acne

• DermWorld Insights and Inquiries: Anticipating Iceland — Ice-pack dermatosis

• Derm Coding Consult: CMS creates permanent drug code for treating molluscum contagiosum

• Safety of dermatologic medication use in lactation

• Patient reviews and their impact on dermatologists

April 3, 2024:

• Safety of DEET insect repellent in children: Do the natural alternatives work?

• DermWorld Insights and Inquiries: Hair straightening and acute renal injury — The latest data straight up

• DermWorld Coding Consult: CMS finalizes and implements evaluation and management visit complexity HCPCS add-on code G2211

• Consensus statements for treating CCCA

• Open Payments review period open through May 15

March 27, 2024:

• Spironolactone: Risk of breast, gynecologic malignancies

• DermWorld Insights and Inquiries: Always another worry for patients with hidradenitis suppurativa — Amyloid A amyloidosis

• FDA approves spesolimab for the treatment of generalized pustular psoriasis

• Refractory keloids: Combined bleomycin and triamcinolone injection

• Delusions of parasitosis: Biometric, pharmaceutical associations

March 20, 2024:

• Combination imiquimod and 5-FU for treating AKs

• DermWorld Insights and Inquiries: San Diego AAD musings

• Talking points: Benzene found in acne care products

• Safety of dermatologic medications in pregnancy

• Itraconazole vs. itraconazole + luliconazole for dermatophytosis

• CMS announces reopening of the 2023 MIPS EUC application in response to change healthcare cyberattack: Now Open Until April 15.

March 13, 2024:

• Men with androgenetic alopecia may benefit from platelet-rich plasma

• DermWorld Insights and Inquiries: Coming clean on chlorhexidine-induced dermatoses

• Roflumilast for the treatment of seborrheic dermatitis

• Potential sexual transmission of T. indotineae

• High levels of benzene detected in benzoyl peroxide acne treatments

March 6, 2024:

• Benzyl benzoate vs. permethrin in treating scabies

• DermWorld Insights and Inquiries: Hemochromatosis — Beyond 50 shades of gray

• Oral acitretin plus topical triamcinolone vs. topical triamcinolone for oral lichen planus

• Deucravacitinib in patients with scalp psoriasis

• Outcomes of same-day treatment with chemical peel and neurotoxin

Feb. 28, 2024:

• Ciclosporin vs. methotrexate for young patients with atopic dermatitis

• DermWorld Insights and Inquiries: Taming toxic erythema of chemotherapy with high-dose vitamin D

• Moisturizing cream with 20% urea for treatment of keratosis pilaris

• Topical estradiol for treating female patients with adult acne

• Basal cell carcinoma: Patterns of metastasis

Feb. 21, 2024:

• Treating keloids, hypertrophic scars with dupilumab

• DermWorld Insights and Inquiries: Alaskapox — The beat goes on

• Cosmetic dermatologic procedures performed by physicians vs. non-physicians

• Outcomes of same-day treatment with chemical peel and neurotoxin

• Vacation days and physician burnout

Feb. 14, 2024:

• Topical tofacitinib for lichen planopilaris, frontal fibrosing alopecia

• DermWorld Insights and Inquiries: Caveat mTOR revisited — Neurofibromatosis

• Risk factors for development of tinea pedis, onychomycosis

• Mpox continues to circulate in the U.S.: Clinical clues and management resources

• Is there an association between psychiatric conditions and rosacea?

Feb. 7, 2024:

• Androgenetic alopecia: topical minoxidil vs. low-dose oral minoxidil

• DermWorld Insights and Inquiries: Short anagen syndrome — The long and short of it

• Skin cancer incidence in patients with hidradenitis suppurativa

• Diagnosing and managing nail psoriasis, nail lichen planus

• Syphilis cases on the rise

• CMS field testing new cost measure for non-pressure ulcers, informational webinar scheduled for Feb. 14

Jan. 31, 2024:

• Dupilumab vs. upadacitinib for atopic dermatitis

• DermWorld Insights and Inquiries: Early-onset hypertension associated with extensive capillary malformations — A new worry to raise dermatologists’ blood pressure

• AAD releases updated acne guidelines

• Multiple biologic failure in psoriasis

• Clinical factors indicating the presence and invasiveness of nail unit melanoma in patients with longitudinal melanonychia

• Academy update on Medicare payment reform

Jan. 24, 2024:

• Micrographic surgery vs. conventional excision: Reducing rates of BCC, SCC

• DermWorld Insights and Inquiries: Senile gluteal dermatosis — The term ‘senile’ is getting old and should be retired

• Overuse of antifungal treatments could be driving drug-resistant disease

• Atypical cutaneous findings of hand-foot-mouth disease

• Safety of biologic therapy in combination with methotrexate in patients with psoriasis

Jan. 17, 2024:

• Risk of skin cancers in patients with actinic keratoses

• DermWorld Insights and Inquiries: A cold abscess remains a cold case — Multiple neonatal staphylococcal cold abscesses of the large folds

• Oral JAK inhibitors for AD patients: Major adverse cardiovascular events

• Sulfites: The 2024 Allergen of the Year

• Immune checkpoint inhibitors: Cutaneous AEs and survival prognosis

Jan. 10, 2024:

• Intralesional MMR vaccine after failure of intralesional Candida antigen in patients with recalcitrant warts

• DermWorld Insights and Inquiries: Beyond disfigurement — The potential for keratinocyte carcinoma in discoid lupus

• FDA approves new drug for molluscum contagiosum

• Clascoterone cream for acne patients

• Statins and risk of skin cancer

• FDA probes hair loss, other potential weight-loss drug side effects

• MIPS data submission period open

Jan. 3, 2024:

• Efficacy of minoxidil for cancer treatment–induced hair loss

• DermWorld Insights and Inquiries: Malignant syphilis — History in the making

• Most effective medications for plaque psoriasis

• Cardiovascular, venous thromboembolism risk associated with JAK inhibitors

• Positive patch test in patients with frontal fibrosing alopecia

Dec. 20, 2023:

• Surgical excision vs. 5-FU vs. PDT in treating Bowen’s disease

• DermWorld Insights and Inquiries: Holiday Greeting 2023

• Association between JAK inhibitors and acne

• Risk of mortality after melanoma in situ diagnosis

• Postoperative bleeding complications associated with novel oral anticoagulants in patients who underwent Mohs surgery

Dec. 13, 2023:

• Isotretinoin exposure and risk of adverse male sexual health outcomes in acne patients

• DermWorld Insights and Inquiries: Sparking the interest in Spark nevus

• Metronidazole for patients with oral lichen planus?

• Expertise, degree of oversight at U.S. medical spas

• Impact of automatic release of dermatology test results on patient emotions, trust

Dec. 6, 2023:

• iPLEDGE wins: FDA to implement AADA’s recommendations

• DermWorld Insights and Inquiries: Aquagenic pruritus and polycythemia vera: Still valid (and mysterious) after all these years

• Treatment access burdens for comorbidities related to atopic dermatitis

• Risk of malignancies in psoriasis patients treated with IL-17, IL-23 inhibitors

• Treatment of alopecia areata with upadacitinib

• Reducing documentation burden: Pilot program for AI voice assistant seeks participants

• FDA evaluates plastic syringes made in China

Nov. 29, 2023:

• Effects of probiotic supplementation in adults with atopic dermatitis

• DermWorld Insights and Inquiries: Sweet sounds of the “SKINphony” — Incorporating music into daily dermatologic practice

• Is flutamide gel effective in treating patients with acne?

• Risk of skin cancer in patients with atopic dermatitis receiving UV-B phototherapy

• Requesting input: 2022 MIPS cost data to help avert payment penalties

• Review your 2023 MIPS eligibility status

Nov. 15, 2023:

• Platelet-rich plasma vs. minoxidil in androgenetic alopecia treatment

• DermWorld Insights and Inquiries: The woolly culprit — Lanolin revealed as an uncommon cause of dermatitis on normal skin

• Medicare Physician Fee Schedule Final Rule highlights

• Diagnosis and management of acral pigmented lesions

• AAD receives $100,000 grant to improve diagnostic excellence

• Topical application of synthetic melanin promotes tissue repair

• Changes to MIPS preliminary scores

• MIPS automatic EUC applies to designated areas in Florida, Georgia

Nov. 8, 2023:

• Terbinafine for onychomycosis: Continuous- vs. pulse-dose

• DermWorld Insights and Inquiries: NSA (neutrophilic sebaceous adenitis) secrets revealed

• AAD releases updated guidelines for atopic dermatitis

• FDA approves secukinumab for hidradenitis suppurativa

• FDA approves interchangeable biosimilar for plaque psoriasis

• MIPS data validation and audit to begin

Nov. 1, 2023:

• Can oral nutraceuticals reduce isotretinoin side effects?

• DermWorld Insights and Inquiries: Exchanging plasma exchange for a novel approach — The potential of FcRn antagonists in dermatologic autoimmune disease

• Risk of rebound psoriasis flare from systemic corticosteroids

• Gut microbiome in patients with melanoma

• Impact of automatic release of dermatology test results on patient emotions, trust

Oct. 25, 2023:

• Can oral nutraceuticals reduce isotretinoin side effects?

• DermWorld Insights and Inquiries: NSA (neutrophilic sebaceous adenitis) secrets revealed

• Risk of rebound psoriasis flare from systemic corticosteroids

• Gut microbiome in patients with melanoma

• Impact of automatic release of dermatology test results on patient emotions, trust

Oct. 18, 2023:

• Risk factors for subsequent primary melanoma in patients with previous melanoma

• DermWorld Insights and Inquiries: Wolf’s isotopic response — Where and when

• Derm Coding Consult: Q&A on repair of contiguous defect in multiple anatomic locations

• Advocacy win: FDA extends flexibilities for iPLEDGE REMS Program

• FDA approves nivolumab for adjuvant treatment of Stage IIB/C melanoma

• AADA advocacy results in House Committee to hold Medicare physician payment hearing

Oct. 11, 2023:

• Is clascoterone effective for mild hidradenitis suppurativa?

• DermWorld Insights and Inquiries: Dermatologists should not be in the dark about kratom

• How often does scabies treatment fail?

• Low-dose omalizumab for patients with chronic spontaneous urticaria

• AADA prompts FDA to make vital changes to iPLEDGE program

• Sodium bicarbonate, lidocaine injections recalled

Oct. 4, 2023:

• Dermoscopic predictors of melanoma in small-diameter melanocytic lesions

• DermWorld Insights and Inquiries: The Venetian antithesis – Treating median canaliform nail dystrophy

• Risk between history of rosacea and risk of BCC of the face

• Adalimumab with methotrexate vs. adalimumab monotherapy in psoriasis patients

• ChatGPT: Generating patient-facing and clinical responses for melanoma

Sept. 27, 2023:

• Is roflumilast effective in patients with seborrheic dermatitis?

• DermWorld Insights and Inquiries: Diminishing diagnostic cognitive bias — Anchors away

• JAK inhibitors for granulomatous dermatoses

• Is there an association between atopic dermatitis and alopecia areata?

• Survival outcomes after Mohs surgery in patients with early-stage MCC

• Reminder: AMA-Mathematica physician practice expense survey 

Sept. 20, 2023:

• Reliable, rapid identification of terbinafine resistance in dermatophytic nail and skin infections

• DermWorld Insights and Inquiries: Can tocilizumab deep six recalcitrant morphea?

• Trends in hair, skin, and nails supplement use

• Tapering of dupilumab in atopic dermatitis patients with low disease activity

• AADA members and patients take message to Capitol Hill at 2023 Legislative Conference

• AADA hosted physician summit on Medicare payment

• CMS announces MIPS EUC for applicable Hawaii counties

Sept. 13, 2023:

• Are psoriasis biologics safe during conception, pregnancy?

• DermWorld Insights and Inquiries: Promising therapeutic developments for cutaneous lupus erythematosus: Interfering with interferon – Part II – Focus on anifrolumab

• Acne vulgaris guidelines: Member comment period is open

• AAD Pathways program highlights the Academy’s pipeline efforts

• AADA hosted physician summit on Medicare payment

• CMS offers resources, flexibilities in response to Hurricane Idalia

Sept. 6, 2023:

• Chemoprevention of keratinocyte carcinoma with imiquimod, 5-FU, and tretinoin

• DermWorld Insights and Inquiries: Can tocilizumab deep six recalcitrant morphea?

• Vitiligo patients may have reduced incidences of skin cancer

• Dermatology drugs make Medicare’s price negotiation list

• Clinical factors, hair care practices influencing outcomes in patients with CCCA

Aug. 30, 2023:

• Does low-dose oral minoxidil improve hair density in traction alopecia?

• DermWorld Insights and Inquiries: A medal-worthy diagnosis: Medallion-like dermal dendrocyte hamartoma

• Methotrexate: Drug survival and predicative factors for discontinuation in psoriasis patients

• Perioperative antiplatelet, anticoagulant medication management in dermatosurgery

• Now available: MIPS performance feedback

• Virtual physician summit on Medicare payment reform

Aug. 23, 2023:

• Efficacy of upadacitinib in patients with recalcitrant vitiligo

• DermWorld Insights and Inquiries: Vascular abnormalities in FFA, artificial intelligence, and Winston Churchill

• Efficacy of tretinoin cream in treating acanthosis nigricans

• Patch test reactions to limonene and linalool

• Dermatologist expertise needed: Increased rates of laser-induced scarring

Aug. 16, 2023:

• Off-label use of calcineurin inhibitors for dermatologic conditions

• DermWorld Insights and Inquiries: Diagnosing nail unit melanomas at a faster clip

• What are risk factors for developing generalized pustular psoriasis?

• AADA urges FDA, manufacturers take more action on lidocaine shortage

• RNA sampling via tape strips may rule out melanoma in suspicious lesions

Aug. 9, 2023:

• Emerging treatments for itch in atopic dermatitis

• DermWorld Insights and Inquiries: Prior authorization audits and innovations — Are we finally reducing the (PA)in?

• Adverse events in patients with alopecia areata treated with JAK inhibitors

• AMA finds nearly 1 in 3 physicians report being sued at least once

• Do top-selling brand-name drugs in Medicare have added therapeutic benefit?

• AADA urges dermatologists to respond to AMA-Mathematica Physician Practice Expense Survey to ensure accurate Medicare pay rates

Aug. 2, 2023:

• Isotretinoin for seborrheic dermatitis: A review

• DermWorld Insights and Inquiries: Cellular neurothekeoma: A tribute to Barnhill and Mihm and a remembrance of Martin C. Mihm Jr., MD

• AADA analyzes impact on dermatology from proposed Medicare Fee Schedule

• Is nasal decongestant oxymetazoline a novel therapeutic option for post-acne erythema?

• Patient preferences for pain control after Mohs surgery

July 26, 2023:

• Intralesional HPV vaccine may clear recalcitrant warts

• DermWorld Insights and Inquiries: Cycling back to doxycycline’s roots as therapy for bullous pemphigoid

• FDA approves first molluscum contagiosum treatment

• Does remission for psoriasis patients mean they can discontinue biologics?

• Antibiotic shortage may worsen syphilis epidemic

July 19, 2023:

• Use of hair oils to treat androgenetic alopecia

• DermWorld Insights and Inquiries: The intimate dance of Staphylococcus aureus and cutaneous T-cell lymphoma

• Imiquimod for management of lentigo maligna

• An antioxidant in medical devices that may cause allergic contact dermatitis

• AAD launches TikTok account

• FDA reports risk of delayed onset inflammation near dermal filler treatment sites

July 12, 2023:

• Association between hydrochlorothiazide use and nonmelanoma skin cancer

• DermWorld Insights and Inquiries: After 23 years, a syndrome converted me into an eflornithine believer

• Potential applications of ChatGPT in dermatology

• JAK inhibitors for lichen planus

• JAAD ranks No. 1 among dermatology journals for fourth year running

• Academy involved at White House Fourth of July celebration

July 5, 2023:

• Petroleum jelly: Safety, myths, and misconceptions

• DermWorld Insights and Inquiries: Reflections on reflectance confocal microscopy for diagnosing benign lichenoid keratoses

• Managing CLE with JAK inhibitors

• Homelessness associated with increased rates of skin conditions

• Occupational contact allergy: Trends in sensitization

• Treatment recommendations for acne-associated hyperpigmentation

June 28, 2023:

• A beneficial botanical extract for actinic keratosis?

• DermWorld Insights and Inquiries: Dermatologic ergonomics — Straighten up and fly right

• FDA approves alopecia areata treatment in adults and teens

• AAD launches innovative project to improve outcomes for patients with generalized pustular psoriasis

• An antioxidant in medical devices that may cause allergic contact dermatitis

• CMS opens MIPS Final Score Preview period, hardship exemption applications open

• AAD’s Good Skin Knowledge program receives vitiligo awareness award

June 21, 2023:

• Methotrexate vs. methotrexate plus prednisone in patients with alopecia areata totalis, universalis

• DermWorld Insights and Inquiries: Turning a blind eye on second opinions

• Nail clipping histopathology for routine evaluation of melanonychia

• Risk of infection in children with psoriasis treated with ustekinumab, etanercept, or methotrexate

• Dermatology topics tested in question banks for medical students

June 14, 2023:

• Truncal acne in young adults

• DermWorld Insights and Inquiries: Teatime for radiation dermatitis (and beyond)

• Comorbidities of keloid and hypertrophic scars

• Misconceptions about biosimilars in dermatology

• Physicians should remain vigilant in identifying, preventing mpox

June 7, 2023:

• Treatments for pseudofolliculitis barbae

• DermWorld Insights and Inquiries: Taking it on the shin – part two

• Efficacy of abrocitinib for the treatment of lichen sclerosus?

• Scientists find potential treatment for rare genetic skin disorder

• Academy Advisory Board invites members to submit policy resolutions by July 3

May 31: 2023:

• Cause or cure: Dupilumab and alopecia areata

• DermWorld Insights and Inquiries: Taking it on the shin – part 1

• A simplified dermoscopic algorithm for melanoma diagnosis

• FDA approves Merkel cell carcinoma treatment

• Is metformin effective for dermatologic conditions?

May 24, 2023:

• Mood changes in adolescent patients taking isotretinoin

• DermWorld Insights and Inquiries: Tinea gone wild — The emergence of Trichophyton indotineae as a global phenomenon

• Successful dose reduction of dupilumab in AD patients

• ChatGPT in academic medicine

• Lanolin-induced contact dermatitis

May 17, 2023:

• What topical psoriasis treatments do patients prefer?

• DermWorld Insights and Inquiries: Leadership succession: Sunrise, sunset

• FDA extends approval of at-home pregnancy tests under iPLEDGE

• CDC announces first reported U.S. cases of tinea caused by Trichophyton indotineae

• AADA gains critical clarification on Aetna’s Claim and Coding Review Program

• FDA update: Use of Renuvion/J-Plasma device for certain aesthetic procedures

• Watching for signs of Marburg virus disease, non-itchy rash

• Academy Advisory Board invites members to submit policy resolutions by July 3

May 10, 2023:

• Is spironolactone use for acne associated with increased risk for venous thromboembolism?

• DermWorld Insights and Inquiries: PRAME sets its eyes on the road to fame

• How effective is oral ivermectin for scabies patients?

• GPP treatment receives FDA breakthrough therapy designation

• Former AAD president to address cutaneous manifestations of fungal infections, emerging drug-resistant species

• Prepare your practices for Cigna’s modifier 25 policy

May 3, 2023:

• Oral oxybutyloride for hidradenitis suppurativa patients?

• DermWorld Insights and Inquiries: Necrobiosis lipoidica in a Wink

• Exposure to anesthesia and alopecia areata

• Do study authors accurately report financial disclosures?

• Higher melanoma rates found among pilots

April 26, 2023:

• Paroxetine for refractory erythema of rosacea?

• DermWorld Insights and Inquiries: Demodectic eruptions — More than you mite have imagined

• Nonthermal atmospheric plasma for molluscum and verruca vulgaris

• Elevance Health restarts E/M leveling program

• Prevalence and treatment of onychomycosis in children

• House of medicine sends joint message of support to congressional champions for legislation tying inflationary update to Medicare physician fee schedule

• AADA meets with White House Cancer Moonshot staff

April 19, 2023:

• Acne scars: Low-dose oral isotretinoin monotherapy vs. combined therapy with picosecond laser

• DermWorld Insights and Inquiries: No longer flailing with Flegel disease

• Academy mourns the passing of former Academy executive director Brad Claxton

• DermWorld Young Physician Focus: Workplace ethos is of paramount importance

• Biden Administration labels fentanyl laced with xylazine as ‘emerging threat’

• HIPAA enforcement discretion to end after the PHE

April 12, 2023:

• Perioperative imaging for high-stage cutaneous SCC may guide management

• DermWorld Insights and Inquiries: Triskaidekaphobia legitimized: Fatal Factor XIII deficiency

• Contact allergens in nail products

• DataDerm™: 2022 Annual Report

• Drivers of morality in Merkel cell carcinoma

• Reporting period deadline extended for provider relief funds

April 5, 2023:

• What’s the effect of probiotics on skin photoaging?

• DermWorld Insights and Inquiries: An appealing step closer to targeted topical therapies

• Does nicotinamide prevent keratinocyte cancers in organ recipients?

• FDA advisory committees recommend vital changes to iPLEDGE

• The role of dermatologists in detecting elder abuse

• DEA issues letter on MATE Act training requirements

March 29, 2023:

• Low-dose isotretinoin for severe seborrheic dermatitis?

• DermWorld Insights and Inquiries: Can we chat?

• Risk of melanoma in patients with BC

• Is AD severity correlated with food allergy prevalence?

• FDA grants accelerated approval to Merkel cell carcinoma drug

March 22, 2023:

• Comparing efficacy of JAK inhibitors used in alopecia areata

• DermWorld Insights and Inquiries: Resorcinol’s resourcefulness in hidradenitis suppurativa

• Derm Coding Consult: CMS Targeted Probe and Educate (TPE) reviews are now in full swing

• Lebrikizumab for atopic dermatitis: Two phase 3 trials

• What the end of the COVID-19 PHE means for dermatologists

March 15, 2023:

• Topical cetirizine with minoxidil vs. minoxidil in androgenetic alopecia

• DermWorld Insights and Inquiries: A checkup on immune checkpoint inhibitor-induced subacute cutaneous lupus

• DermWorld Young Physician Focus: Putting the proper safeguards into place

• Safety of UV filters in the U.S. and EU

• Evaluating parental leave policies at medical schools

• FDA reports SCC in capsule around breast implants

March 8, 2023:

• Efficacy of various concentrations of retinol in middle-aged women

• DermWorld Insights and Inquiries: For the win! Championing the use of the term ‘reactive granulomatous dermatitis’ in clinical practice

• Member comment period for new AD guidelines is open

• Should deep shave removal be considered for suspected BCC?

• Former AADA President David Pariser, MD, FAAD, attends President Biden speech, urges president to oppose Medicare cuts

March 1, 2023:

• Isotretinoin: Risk of IBS, ulcerative colitis, and Crohn’s disease?

• DermWorld Insights and Inquiries: Seeing red with dupilumab

• IL-17 inhibitors in psoriasis patients in the real world

• What’s new in the management of cutaneous HPV infection?

• MIPS data submission open, exception deadline approaching

• Keep dermatology’s voice strong: Join the AMA

Feb. 22, 2023:

• How effective are field treatments for actinic keratosis?

• DermWorld Insights and Inquiries: Saving face — The importance of recognizing facial discoid dermatosis

• A systematic review of intralesional treatments for plantar warts

• Risk of needle contamination, complications with hyaluronic acid fillers

• What factors are associated with matching to a dermatology residency?

Feb. 15, 2023:

• AADA addresses lidocaine shortage with manufacturers

• DermWorld Insights and Inquiries: A nail-biting commentary

• Risk of rebound psoriasis flare from systemic corticosteroids

• DermWorld Young Physician Focus: Weighing our options for pediatric care

• Advocacy win: UnitedHealthcare updates prior authorization policy

Feb. 8, 2023:

• A review of newer agents for alopecia areata

• DermWorld Insights and Inquiries: A surgeon’s primary intention is to reduce secondary infection

• CDC investigating possibility of treatment-resistant dermatophytosis

• High-dose clobetasol propionate in patients with cutaneous lichen planus

• Allergens in pediatric sunscreens

Feb. 1, 2023:

• Are topical AK treatments associated with increased risk of SCC?

• DermWorld Insights and Inquiries: A seasoned approach to treating the ‘salt and pepper’ dyspigmentation of systemic sclerosis

• What role does diet play in rosacea?

• Media highlights dermatologists taking action to integrate skin of color into medical training

• Managing patients with DRESS

Jan. 25, 2023:

• Is topical spironolactone effective for acne?

• DermWorld Insights and Inquiries: The ironclad promise of ferroptosis

• Topical lidocaine-prilocaine vs. ice packs for laser hair removal

• Efficacy of tretinoin creams in treating acanthosis nigricans

• Dermatologists’ knowledge of compounding pharmacy regulations

Jan. 18, 2023:

• Have cutaneous manifestations of COVID-19 changed during Delta, Omicron waves?

• DermWorld Insights and Inquiries: Complications of silicone injections – persistence, stigma, and treatment

• AAD releases updated topical therapy guidelines for atopic dermatitis

• DermWorld Young Physician Focus: Juggling parenting and dermatology

• AMA House of Delegates recap

• COVID-19 Public Health Emergency renewed

Jan. 11, 2023:

• Antihistamines as adjunct therapy for alopecia areata

• DermWorld Insights and Inquiries: Acquisition and loss — A tribute to Jouni Uitto, MD, PhD

• Lidocaine shortage: Ask the expert

• Nail clipping histopathology for routine evaluation of melanonychia

• Academy Advisory Board invites members to submit policy resolutions

Jan. 4, 2023:

• Frontal fibrosing alopecia, sunscreen, and actinic damage

• DermWorld Insights and Inquiries: Sniffing out the meaning of perialar intertrigo

• Topical eye medications causing allergic contact dermatitis

• Achieving an itch-free state using topical ruxolitinib

• Deadline extended for MIPS Extreme and Uncontrollable Circumstances exception application

• Academy Advisory Board invites members to submit policy resolutions

Dec. 21, 2022:

• Isotretinoin and the risk of psychiatric events in acne patients

• DermWorld Insights and Inquiries: Holiday greeting 2022

• Risk of skin cancer in patients with chronic cutaneous inflammatory conditions

• Do e-cigarettes affect cutaneous wound healing?

• Treating hidradenitis suppurativa with upadacitinib

Dec. 14, 2022:

• Are nutritional supplements effective for hair loss?

• DermWorld Insights and Inquiries: A Frank discussion about earlobe creases

• DermWorld Young Physician Focus: Zoonotic dermatoses – When the rare and unusual move next door

• A consensus statement on measuring AD control, itch in clinical practice

• How well do patients understand common medical jargon?

• 2022 MIPS: Exemption application

Dec. 7, 2022:

• Recommendations for follow-up of patients with nonmelanoma skin cancer

• DermWorld Insights and Inquiries: Xylazine (“Tranq”) — The potential for loss of life and limb

• Using apremilast off-label in dermatologic disorders

• How does Instagram portray laser surgery?

• Physician legislators in government in 2022

• MIPS 2022 reminders: Preview period, SAFER Guides measure

Nov. 30, 2022:

• Chemotherapeutics for treating actinic keratosis

• DermWorld Insights and Inquiries: Palmar Pagetoid dyskeratosis — A sheep in wolf’s clothing

• A guide to transitioning to JAK inhibitors for AD patients

• Improving recognition of dermatologic conditions in skin of color

• Physician burnout vs. depression

Nov. 16, 2022:

• Novel treatments for chronic spontaneous urticaria

• DermWorld Insights and Inquiries: Unrestricted fascination with restrictive dermopathy

• DermWorld Young Physician Focus: Academy staff offer refresher on top E/M coding errors

• Selecting the right biologic treatment for psoriasis patients

• Do e-visits for isotretinoin management cause interruptions in care?

Nov. 9, 2022:

• Intralesional vs. intramuscular hepatitis B vaccine for common warts

• DermWorld Insights and Inquiries: Hair straighteners and the risk of uterine cancer — More studies are necessary to get this straight

• Alopecia areata: Two investigational JAK inhibitors report positive results

• Soft tissue dermal filler-associated necrosis

• Contact allergens in natural skin care products

Nov. 2, 2022:

• Factors that influence platelet rich plasma efficacy in androgenic alopecia

• DermWorld Insights and Inquiries: Lipodystrophia semicircularis — A lipoatrophy not to get depressed about

• Underlying conditions associated with development of prurigo nodularis

• Psychological therapies in the management of dermatologic diseases

• Facial dermatoses from face masks

Oct. 26, 2022:

• Diagnosing and treating onychomycosis

• DermWorld Insights and Inquiries: Lending a helping hand to our patients with Dupuytren’s disease

• GoodRx launches provider-facing tool for point-of-care savings

• Distinguishing features of pseudocellulitis in pediatric inpatients

• Deucravacitinib vs. apremilast for plaque psoriasis

Oct. 19, 2022:

• Safety of minoxidil for hair disorders in pediatric patients

• DermWorld Insights and Inquiries: Telangiectasias: When is it TEMPI time?

• DermWorld Young Physician Focus: Revisiting physician mental health

• Monkeypox: Recognizing minimal cutaneous involvement or systemic symptoms

• Is there an association of VTE with AD and treatment with JAK inhibitors?

Oct. 12, 2022:

• Type 2 diabetes and CCCA severity

• DermWorld Insights and Inquiries: Fixing the concept of the neutrophilic fixed drug eruption

• What’s the risk of IBD in patients with chronic inflammatory skin diseases?

• Reduced post-infusion cooling prevents chemotherapy-induced alopecia

• Victory! UHC changes Mohs prior authorization, multiple procedure payment reduction policies

Oct. 5, 2022:

• Is there an association between low-dose methotrexate and melanoma?

• DermWorld Insights and Inquiries: Optimizing the dermatologist-patient encounter

• FDA approves first treatment for prurigo nodularis

• Perioperative practices in dermatologic surgery

• Tacrolimus for treating oral lichen planus

Sept. 28, 2022:

• Treating warts with needle-free fluorouracil injection

• DermWorld Insights and Inquiries: Tag, you’re it!

• Clinical outcomes of chronic urticaria after two years

• Clues to help identify patients with ocular rosacea

• Study compares AI and dermatologist judgments of melanoma thickness

Sept. 21, 2022:

• Does low-dose oral minoxidil affect blood pressure, heart rate?

• DermWorld Insights and Inquiries: The emergence of rituximab-induced pyoderma gangrenosum — An alert to dermatologists

• DermWorld Young Physician Focus: PBM tactics increase drug prices, lower patient access

• Filler reversal with hyaluronidase

• House bill would eliminate Medicare conversion factor cut in 2023

• House passes prior authorization relief bill

Sept. 14, 2022:

• Real-world methotrexate use in pediatric patients with plaque psoriasis

• DermWorld Insights and Inquiries: The ever-changing world of nevus sebaceus

• New anti-wrinkle injection receives FDA approval

• FDA approves first TYK2 inhibitor deucravacitinib

• Managing hair loss after COVID-19 infection

Sept. 7, 2022:

• Are concentrations higher than 5% minoxidil of benefit for androgenic alopecia patients?

• DermWorld Insights and Inquiries: BASCULE syndrome: Is something brewing with Bier spots?

• Emollient creams exhibit diverse effects on skin barriers of AD patients

• Complications with fat and cellulite reduction devices

• AADA responds to Medicare 2023 payment proposals

Aug. 31, 2022:

• Isotretinoin lab monitoring in acne treatment

• DermWorld Insights and Inquiries: Metformin mania — Is it an adequate chemopreventive agent for skin cancer?

• Monkeypox: A dermatologic primer

• AADA, sister societies address drug shortage with FDA

• Characterizing three profiles for bullous pemphigoid

Aug. 24, 2022:

• Comparing efficacy and safety of laser treatments for tattoo removal

• DermWorld Insights and Inquiries: The pressure to prevent pressure ulcers

• Derm Coding Consult: AMA releases new codes for monkeypox virus testing and vaccination

• Ask the expert: Fighting for fair Medicare reimbursement

• AAD mourns the passing of Samuel L. Moschella, MD

Aug. 17, 2022:

• Do dietary exclusions improve atopic dermatitis?

• DermWorld Insights and Inquiries: Promising therapeutic developments for cutaneous lupus erythematosus — Interfering with interferon

• Derm Coding Consult: Dermatology injection code utilization

• DermWorld Young Physician Focus: Pulling back the curtain on pharmacy benefits managers

• At-home treatment of cutaneous warts combining in-person, telederm consultations

Aug. 10, 2022:

• Tetracyclines may pose greater hyperpigmentation risk

• DermWorld Insights and Inquiries: Forty years of marriage, dermatology, inequities, and gratitude

• Registry now accepting monkeypox cases

• AAD statement on National Academies of Sciences, Engineering, and Medicine's report on environmental impact of sunscreens and potential impacts of changes in sunscreen usage

• New federal guidance on nondiscrimination in telehealth services

• FDA issues warning to companies selling unapproved new drugs for mole and skin tag removal

Aug. 3, 2022:

• Dutasteride microinjections with oral minoxidil vs. oral minoxidil for androgenetic alopecia

• DermWorld Insights and Inquiries: Infantile digital fibromatosis – Inclusions and exclusions

• CMS outlines payment changes for 2023 in proposed fee schedule

• FDA approves roflumilast for treatment of plaque psoriasis for patients 12 and older

• Treating patients with skin-picking disorder

July 27, 2022:

• Facial hyperhidrosis: Botulinum toxin A injection vs. topical glycopyrrolate

• DermWorld Insights and Inquiries: JAKne is on the horizon

• Dupilumab for chronic prurigo, chronic idiopathic pruritus

• Safety of Q-switched alexandrite laser in darker skin

• Chlormethine for mycosis fungoides

July 20, 2022:

• FDA approves first vitiligo treatment for skin repigmentation

• DermWorld Insights and Inquiries: A single case report has the potential to change the world — Could JAK inhibition alter the trajectory of multicentric reticulohistiocytosis?

• OIG initiates audit of dermatologist claims using modifier 25

• DermWorld Young Physician Focus: Counseling patients on cosmetic concerns

• June AMA House of Delegates has implications for dermatology

July 13, 2022:

• Androgenic skin conditions and hormonal IUDs

• DermWorld Insights and Inquiries: COVID-19 can nail you in so many ways

• What does Europe’s tattoo ingredient ban mean for North America?

• Lab testing for pediatric patients using isotretinoin

July 6, 2022:

• Long-term recurrence rates of actinic keratoses

• DermWorld Insights and Inquiries: Isotretinoin and diabetes — Of familiarity and surprise

• What physicians should know about monkeypox

• Anti-PD-1 therapy for melanoma patients after achieving a complete response

• Asymptomatic dermatologic surgery patients who test positive for COVID-19

June 29, 2022:

• Psoriasis treatment adherence: Adalimumab vs. ixekizumab

• DermWorld Insights and Inquiries: When to see red in linear erythronychia — Malignant onychopapilloma

• Dermatologist Jack Resneck Jr., MD, FAAD, becomes new AMA president

• Rare cutaneous malignancies in skin of color

• Dermatology residency: Allopathic vs. osteopathic vs. international

June 22, 2022:

• Molluscum contagiosum: 35% trichloroacetic acid vs. autoinoculation

• DermWorld Insights and Inquiries: Is it a waste for dermatologists to order fecal calprotectin?

• Physician experience with virtual scribes

• Derm Coding Consult: Cigna to delay modifier 25 policy

• Ustekinumab for pediatric plaque psoriasis

June 15, 2022:

• FDA approves first systemic treatment for alopecia areata

• DermWorld Insights and Inquiries: Aluminum can cause allergic contact dermatitis — Allergen of the Year 2022

• DermWorld Young Physician Focus: Academy leadership programs position young physicians for success

• FDA approves dupilumab for children 6 months to 5 years of age with AD

• Risk of vitamin D deficiency in Black patients with CCCA

June 8, 2022:

• The administrative burden of prescribing isotretinoin

• DermWorld Insights and Inquiries: Sweating over acquired idiopathic generalized anhidrosis

• AADA counters IPMG objections to iPLEDGE improvements

• Actinic keratosis guidelines updated to reflect tirbanibulin research

• FDA updates recommendations for the use of Renuvion/J-Plasma device

• Topical treatment improves hyperpigmentation in skin of color

June 1, 2022:

• What’s new in adult acne over the last two years?

• DermWorld Insights and Inquiries: Granulomatous cheilitis — Back to the Future

• Derm Coding Consult: Cigna’s new modifier 25 policy

• Adverse events associated with injectable fillers

• FDA approves tapinarof for psoriasis

• MIPS automatic EUC applies to designated areas in New Mexico

May 25, 2022:

• Placebo regrowth rate in alopecia areata trials

• DermWorld Insights and Inquiries: The globalization of monkeypox

• AADA renews calls for iPLEDGE improvements with IPMG, FDA

• Seeking comments on atopic dermatitis guidelines on topical therapies

• Ruxolitinib cream for cutaneous lichen planus

May 18, 2022:

• Abrocitinib efficacy after switching from dupilumab

• DermWorld Insights and Inquiries: Coming to grips with lymphocytic thrombophilic arteritis

• DermWorld Young Physician Focus: Protecting dermatologic scope of practice

• Seeking comments on atopic dermatitis guidelines on topical therapies

• New gel effective for excessive underarm sweating

May 11, 2022:

• Sexual dysfunction associated with finasteride use in men with androgenetic alopecia

• DermWorld Insights and Inquiries: Lagging ahead — LAG-3 checkpoint inhibition for advanced melanoma

• FDA grants fast track designation for ichthyosis therapy

• An analysis of popular HS content on TikTok

• Academy Advisory Board invites members to submit policy resolutions

• 2022 MIPS EUC, Promoting Interoperability hardship exception applications available

May 4, 2022:

• Plantar warts: Local hyperthermia vs. cryotherapy

• DermWorld Insights and Inquiries: Eruptive pseudoangiomatosis is real

• Intralesional methotrexate vs. triamcinolone acetonide for nail matrix psoriasis

• Report shows physician pay is on the rise

• STD surge continues

April 27, 2022:

• A novel treatment for molluscum contagiosum?

• DermWorld Insights and Inquiries: Eye-opening news about oxymetazoline

• Trends in prescribing spironolactone for acne, HS in adolescents

• Racial biases in medical notes may contribute to health disparities

• FDA issues warning about skin lightening products

April 20, 2022:

• Which biologics are most effective for psoriasis?

• DermWorld Insights and Inquiries: One Toker over the line — Clarifying Toker cell hyperplasia in Zuska disease and its relationship to hidradenitis suppurativa

• DermWorld Young Physician Focus: Re-examining itch

• Are specific body sites prone to surgical site infections?

• COVID-19 public health emergency renewed

• The non-physician dermatology workforce

April 13, 2022:

• Is there an association between isotretinoin and adverse neuropsychiatric outcomes?

• DermWorld Insights and Inquiries: Early recognition of rituximab-induced late onset neutropenia is essential

• Election winners Dialogues interview

• Treating seborrheic keratosis with hydrogen peroxide

• IL-17 blockade reduces psoriatic lesional expression of COVID-19 receptor

April 6, 2022:

• A comprehensive review of rosacea treatments

• DermWorld Insights and Inquiries: “Stepping up” to off-label dosing of biologics

• Improving itch in prurigo nodularis patients

• What acne treatments are being recommended on YouTube?

• A review of systemic treatments for vitiligo

March 30, 2022:

• The rankings are in: Minoxidil, finasteride, and dutasteride for male androgenetic alopecia

• DermWorld Insights and Inquiries: Bowel-associated dermatosis-arthritis syndrome (BADAS) — The story behind the acronym

• Acne and insulin resistance

• Health Care Provider Protection Act becomes law

• What dermatologists should know about VEXAS syndrome

March 23, 2022:

• Acitretin: A new therapy for onychomycosis?

• DermWorld Insights and Inquiries: A new wrinkle in the diagnosis of cystic fibrosis?

• Injury and litigation in cutaneous laser surgery

• Switching from oral to subcutaneous methotrexate

• FDA warns against use of Renuvion/J-Plasma device for certain aesthetic procedures

• Extension of COVID-19 telehealth waivers

March 16, 2022:

• Comparing four cSCC staging systems

• DermWorld Insights and Inquiries: Mind the gap

• DermWorld Young Physician Focus: Talking points

• Potassium monitoring in women on spironolactone

• Using medical cannabis to treat dermatologic conditions

March 9, 2022:

• Eight misconceptions about photoprotection in skin of color

• DermWorld Insights and Inquiries: IL-36 and generalized pustular psoriasis — L’chaim!

• Derm Coding Consult: Novitas revises shave removal coverage policy to include malignant skin lesions

• Is spironolactone use associated with risk of cancer?

• MIPS extreme and uncontrollable circumstances applications reopened

March 2, 2022:

• Biotin beware: Physician, patient knowledge about lab interference

• DermWorld Insights and Inquiries: The rhythm of RIME

• Infections in children treated with dupilumab

• Cutaneous adverse events are associated with increased survival in patients on anti-PD-1, anti-PD-L1 therapy

• Will biosimilars cut spending for biologic therapy in the U.S.?

Feb. 23, 2022:

• Frontal fibrosing alopecia: The effects of sunscreens and moisturizers

• DermWorld Insights and Inquiries: The vexing verruciform xanthoma

• DermWorld Young Physician Focus: The patient experience — there’s an app for that

• Red light vs. blue light therapies for acne

• Diversity in dermatology clinical trials

Feb. 16, 2022:

• A review of calcipotriol plus 5-fluorouracil for actinic keratosis

• DermWorld Insights and Inquiries: Vascular Ehlers-Danlos syndrome: From rupture to rapture?

• Delayed complications for FDA-approved HA dermal fillers

• What every physician needs to know about the Disabilities Act

• Safety of tacrolimus for children with AD

Feb. 9, 2022:

• Tinted sunscreens: A practical guide to counseling patients

• DermWorld Insights and Inquiries: Lightening the cutaneous and emotional burden of melasma — cysteamine’s role

• Nemolizumab plus topicals improve AD itch

• Is there an association between alopecia areata and retinal diseases?

• Treating Netherton syndrome with dupilumab

Feb. 2, 2022:

• A high-fiber diet may affect immunotherapy response for melanoma patients

• DermWorld Insights and Inquiries: An old dog with a new trick — High dose intralesional steroids in hidradenitis suppurativa

• Derm Coding Consult: CMS announces new Place of Service code for telehealth provided to patients in their homes

• 2022 physician depression, burnout survey

• Topical calcineurin inhibitors for pediatric atopic dermatitis

Jan. 26, 2022:

• Allergens in hand sanitizers

• DermWorld Insights and Inquiries: Eccrine syringofibroadenoma — Sweating over the details

• Derm Coding Consult: Applying 2021 E/M coding concepts in everyday practice – Part 8

• New AAD guidelines address comorbidities and atopic dermatitis

• FDA approves abrocitinib, upadacitinib for atopic dermatitis

• AMA House of Delegates recap

Jan. 19, 2022:

• Finasteride: Topical vs. oral for male androgenetic alopecia

• DermWorld Insights and Inquiries: Probing pityriasis rosea in pregnancy

• Derm Coding Consult: Dermatology benign, premalignant, and malignant destruction code utilization

• DermWorld Young Physician Focus: To stress is human

• Supreme Court upholds CMS vaccine mandate, strikes down OSHA

Jan. 12, 2022:

• Probiotics for atopic dermatitis?

• DermWorld Insights and Inquiries: Tarrying for tapinarof

• Derm Coding Consult: Patch testing unit of service reduction averted

• Research gap years may impact successful dermatology match

• Patient satisfaction with live video telehealth declines

Jan. 5, 2022:

• Cicatricial alopecia following ACD from hair dye

• DermWorld Insights and Inquiries: Coming full circle (almost) — Low dose oral minoxidil for alopecia

• FDA approves atopic dermatitis biologic

• Risk factors for positive surgical margins after excision of MCC

• Academy Advisory Board invites members to submit policy resolutions

Dec. 22, 2021:

• Can COVID-19 be transmitted through the skin?

• DermWorld Insights and Inquiries: Holiday greeting 2021

• Derm Coding Consult: Anthem updates virtual visit policies

• No Surprises Act takes effect Jan. 1, 2022

• An emerging preservative allergen?

Dec. 15, 2021:

• Female-pattern hair loss: Effect of bicalutamide on minoxidil-induced hypertrichosis

• DermWorld Insights and Inquiries: Speculating on spicules — Our incomplete knowledge of trichodysplasia spinulosa

• DermWorld Young Physician Focus: I’m not the enemy

• Congress addresses impending Medicare cuts

• Is phototherapy an effective treatment for atopic dermatitis?

Dec. 8, 2021:

• Factors that may predict chronic spontaneous urticaria recurrence

• DermWorld Insights and Inquiries: Propranolol and neutrophilic dermatoses — Can beta-blockade be better blockade?

• Feedback requested: Actinic keratosis clinical guideline update

• 2021 Annual Report of DataDerm™

• iPLEDGE deadline approaching

Dec. 1, 2021:

• Risk of COVID-19 infection in atopic dermatitis patients

• DermWorld Insights and Inquiries: The nexus of VEXAS syndrome

• Skin and gut microbiome in hidradenitis suppurativa

• Is imiquimod cream effective for keratoacanthomas?

• Eye care products that may cause patch test reactions

• CMS, OSHA vaccination deadline approaching

• Reminder: Check your final 2021 MIPS eligibility status

Nov. 17, 2021:

• Intralesional acyclovir for cutaneous warts

• DermWorld Insights and Inquiries: Biotin supplementation for hair and nail health — Does it pass the test?

• DermWorld Young Physician Focus: Making progress

• AADA urges iPLEDGE sponsors to delay new platform implementation

• Pityriasis rubra pilaris-like eruption after mRNA COVID-19 vaccine

• All individual MIPS clinicians to receive automatic extreme and uncontrollable circumstances exemption

Nov. 10, 2021:

• CMS, OSHA release rules expanding workforce vaccination requirements

• DermWorld Insights and Inquiries: Recognizing toxic epidermal necrolysis-like acute cutaneous lupus erythematosus ASAP

• Prognostic value of lymphovascular invasion in early-stage Merkel cell carcinoma

• Sunscreen use and blood concentrations of benzene

• Does exercise influence skin aging, skin health, or androgenetic alopecia?

Nov. 3, 2021:

• Facial contact dermatitis from cosmetic allergens

• DermWorld Insights and Inquiries: Humbled again — Alopecic and aseptic nodules of the scalp

• Derm Coding Consult: Applying 2021 E/M coding concepts in everyday practice – Part 7

• Progression of frontal fibrosing alopecia in Black women

• What UnitedHealthcare’s Designated Diagnostic Provider program may mean for you: Protect your referral relationship with your dermatopathologist

Oct. 27, 2021:

• COVID-19 and nails: A review of clinical findings

• DermWorld Insights and Inquiries: Taking woolly hair to heart

• Derm Coding Consult: CMS revises Advance Beneficiary Notice of Non-coverage (ABN) requirements

• Categorization of cutaneous COVID-19 vaccine reactions

• FDA approves first interchangeable biosimilar to adalimumab

• Facing a trifecta of Medicare physician payment cuts Jan. 1, 2022, here’s what the AADA is demanding on behalf of the specialty

Oct. 20, 2021:

• AADA advocacy results in FDA approving iPLEDGE modifications

• DermWorld Insights and Inquiries: Probing pediatric pigmented purpuras

• DermWorld Young Physician Focus: Staying connected

• Scabies treatment may be less effective

• Hidradenitis suppurativa hospital readmission rate

• AAD mourns the passing of Gloria Flippin Graham, MD, who helped establish the Women’s Dermatologic Society

• HHS renews public health emergency

Oct. 13, 2021:

• How does wearing occlusive gloves impact hand eczema?

• DermWorld Insights and Inquiries: What’s up in Down syndrome?

• Relief funds available for health care providers, including some reserved for rural practices. Apply by Oct. 26.

• New AAD-supported ICD-10 codes for moisture-associated skin damage approved

• FDA warns against use of needle-free devices for dermal filler injections

• CMS updates MIPS 2022 payment adjustments, 2020 MIPS performance feedback

• United adjusts dermpath program, delays until 2022

Oct. 6, 2021:

• A review of oral nail growth supplements

• DermWorld Insights and Inquiries: Granular detail on granular parakeratosis

• Coding guidance on reporting lesion services

• Implementation of COVID-19 phototherapy guidelines

• FDA recalls compounding pharmacy products

Sept. 29, 2021:

• Is HPV vaccination associated with clearance of common warts?

• DermWorld Insights and Inquiries: Positively perplexing — Determining the meaning of CD30 positivity

• FDA proposes new guidance on OTC sunscreen products and safety information

• FDA approves first topical JAK inhibitor for atopic dermatitis

• COVID-19 infection in a vaccinated health system

Sept. 22, 2021:

• What treatment is most effective for refractory spontaneous urticaria?

• DermWorld Insights and Inquiries: Following up on “A Trend I Cannot Endorse”

• DermWorld Young Physician Focus: Serendipity

• Lawsuit filed against FDA for alleged inaction on hair loss drug potential side effects

• Dermatologist Seemal R. Desai, MD, FAAD, reappointed to FDA Pharmacy Compounding Advisory Committee

• Hurricane Ida triggers MIPS extreme and uncontrollable circumstances policy

Sept. 15, 2021:

• Worsening psoriasis after COVID-19 vaccination

• DermWorld Insights and Inquiries: Is ivermectin an old drug with new tricks?

• Frontal fibrosing alopecia and facial care products

• Biden administration announces employee vaccination mandates

• Do hormones, reproduction play a role in incident rosacea?

Sept. 8, 2021:

• A review of spironolactone for androgenetic alopecia

• DermWorld Insights and Inquiries: Alarming but benign – The enigma of acute hemorrhagic edema of infancy

• What are the long-term clearance rates for actinic keratosis interventions?

• FDA issues safety warning for JAK inhibitors that treat inflammatory conditions

Sept. 1, 2021:

• Which dermatology patients should receive a third dose of mRNA vaccine?

• DermWorld Insights and Inquiries: Shedding light on the hydroa vacciniforme-like lymphoproliferative disorder

• Obesity, diabetes associated with reduced response to biologics

• No-show rate reduced with teledermatology

• Information blocking: Make your voice heard

Aug. 25, 2021:

• TNF inhibitors vs. IL-17/IL-23 inhibitors for psoriasis and PsA

• DermWorld Insights and Inquiries: Immediate pathology report release to patients — Is the 21st Century CURES Act worse than the disease?

• Itch in skin of color

• Quantifying skin conditions from mask-wearing

• 2020 MIPS performance feedback, final score, and 2022 payment adjustment

Aug. 18, 2021:

• Evaluating diagnostic accuracy across Fitzpatrick phototypes, skin of color

• DermWorld Insights and Inquiries: Striving for hard facts about water softening in atopic dermatitis

• DermWorld Young Physician Focus: Fitting it all in

• Seeking comments on urticaria guideline

• COVID-19 breakthrough infections in vaccinated health care workers

Aug. 11, 2021:

• Topical tofacitinib for alopecia areata affecting facial hair

• DermWorld Insights and Inquiries: Monitoring infantile hemangiomas — What’s the score?

• Is there an effective treatment for skin picking disorder?

• Chilblains before and during the COVID-19 pandemic

• Efficacy of ruxolitinib cream in vitiligo patients

Aug. 4, 2021:

• Probiotic supplements improve atopic dermatitis symptoms

• DermWorld Insights and Inquiries: Keeping abreast of drug-induced cutaneous lupus

• From mentoring LGBT dermatologists, to caring for HIV patients, GALDA looks back on its 40-year journey

• FDA approves treatment for adult dermatomyositis

• Overcoming hurdles in telemedicine

July 28, 2021:

• OTC hair growth therapies for skin of color patients

• DermWorld Insights and Inquiries: Putting a finger on the diagnosis of Achenbach syndrome

• Celiac disease: Which skin conditions may be related?

• Here’s what it takes to launch a successful Skin Cancer Awareness Month

• A review of TYK2 inhibitors for dermatologic conditions

July 21, 2021:

• AADA secures iPLEDGE win

• DermWorld Insights and Inquiries: Getting to the heart of neonatal lupus erythematosus

• DermWorld Young Physician Focus: Advancing the cause

• Cutaneous reactions after mRNA COVID-19 vaccines

• AMA House of Delegates adopts two resolutions: Non-physician titles, information-blocking rules

July 14, 2021:

• Acne scarring treatments: What’s most effective?

• DermWorld Insights and Inquiries: Assessing the significance of a Long-Developed Habit — The role of LDH in dermatology

• Derm Coding Consult: Applying 2021 E/M coding concepts in everyday practice – Part 6

• Share your comments on the AD comorbidity guideline

• CMS makes sweeping changes to MIPS quality benchmarks

• JAAD ranks No. 1 among dermatology journals

July 7, 2021:

• OTC eczema products with high prevalence of potentially allergenic ingredients

• DermWorld Insights and Inquiries: Progress in pemphigus — Solidifying rituximab’s role

• Share your comments on the AD comorbidity guideline

• An open notes experiment before the information blocking rule

• Sun-damaged skin and subsequent development of cutaneous squamous cell carcinoma

• Provider Relief Fund reporting deadline extended

June 30, 2021:

• Treating atopic dermatitis with cognitive behavioral therapy: Does it work?

• DermWorld Insights and Inquiries: Deep learning in dermatopathology

• Sublingual tofacitinib for alopecia areata

• Biologic psoriasis treatments and risk of nonmelanoma skin cancers

• AAD adopts updated ACCME disclosure standards for educational presenters

• AADA's Coding Community will close permanently Aug. 2, 2021

June 23, 2021:

• Subcutaneous vs. oral methotrexate for psoriasis patients

• DermWorld Insights and Inquiries: Dermatology and dermatopathology awake — now is the time to embrace the AI revolution

• Young Physician Focus: Looking back and forging ahead

• OSHA mandates COVID-19 safety plans for health care workplaces

• Is male frontal fibrosing alopecia linked to sunscreen, hair care products?

• AAD mourns the passing of Robert J. Friedman, MD, MSc

• Join efforts to increase COVID-19 vaccination rates

June 16, 2021:

• Rituximab vs. mycophenolate mofetil for pemphigus vulgaris

• DermWorld Insights and Inquiries: Like the tumor itself, knowledge about DFSP is expanding wider and deeper

• Derm Coding Consult: Applying the 2021 E/M coding concepts in everyday practice – Part 5

• Methotrexate may decrease effectiveness of Pfizer-BioNTech COVID-19 vaccine

• Academy member chosen as AMA president-elect

• Provider Relief Fund reporting deadline extended

June 9, 2021:

• Merkel cell carcinoma survival by anatomic site

• DermWorld Insights and Inquiries: Insult to injury — COVID-19-associated mucormycosis

• Microneedling with topical therapies for melasma

• Photosensitivity reaction from benzodiazepines

• Does wildfire air pollution increase atopic dermatitis, itch appointments?

• AADA opposes physician assistant name change

June 2, 2021:

• Acne and enthesitis: Is there an association?

• DermWorld Insights and Inquiries: Touching on contact pemphigus and pemphigus-like eruptions due to imiquimod

• Derm Coding Consult: Applying 2021 E/M coding concepts in everyday practice – Part 4

• Cutaneous adverse events of immune checkpoint inhibitors

• Pharmaceutical testing detects high levels of benzene in some sunscreen products

• Timolol as a high-value treatment for wounds

• DataDerm™: 2020 MIPS reporting brief

May 26, 2021:

• Managing itch: Wearable sensor quantifies symptoms

• DermWorld Insights and Inquiries: Stevens-Johnson Syndrome-toxic epidermal necrolysis — The aftermath

• Bringing diversity to Academy committees and task forces

• Is abrocitinib effective for moderate-to-severe atopic dermatitis patients?

• AMA survey shows more than 50% of physicians work outside private practice

• CMS reweights MIPS cost category

May 19, 2021:

• Differentiating early squamous cell carcinoma from actinic keratosis

• DermWorld Insights and Inquiries: Epidemic of melanoma or epidemic of scrutiny?

• AAD Board selects Keyvan Nouri, MD, MBA, as next assistant secretary-treasurer

• DermWorld Young Physician Focus: Coming through the other side

• Older Americans turn to online ratings to choose physicians

• Apply for a research grant to support understudied hair disorders

• FDA publishes notice about environmental impact of certain sunscreen ingredient

May 12, 2021:

• Telogen effluvium diagnosis during the COVID-19 pandemic

• DermWorld Insights and Inquiries: For patients with erythropoietic protoporphyria the tide has come in

• Derm Coding Consult: How does your use of benign and malignant excision codes compare to the derm average?

• Clear vs. standard masks during outpatient surgical encounters

• Nationwide global period audit underway

• Comparative effectiveness trials for topical medications

May 5, 2021:

• Is dutasteride an effective treatment for frontal fibrosing alopecia?

• DermWorld Insights and Inquiries: Digging deeper into lupus erythematosus panniculitis

• Which herbal supplements may affect autoimmune skin diseases?

• Risk of allergic reaction to COVID-19 vaccine low among patients with allergic skin diseases

• Grant opportunity: Help increase minority representation in lupus-related clinical trials

• Academy Advisory Board invites members to submit policy resolutions

April 28, 2021:

• Acne: Clindamycin-tretinoin vs. benzoyl peroxide-adapalene

• DermWorld Insights and Inquiries: Do not get burned by missing Staphylococcal scalded skin syndrome

• Is daylight photodynamic therapy effective for actinic keratosis?

• Derm Coding Consult: Applying 2021 E/M coding concepts in everyday practice – Part 3

• OIG plans report on dermatologist use of modifier 25

• Comorbidity screening for hidradenitis suppurativa patients

• What does the PHE extension mean for telehealth codes?

April 21, 2021:

• Do hydrolyzed collagen supplements affect skin aging?

• DermWorld Insights and Inquiries: Nailing down the treatment for ungual melanoma in situ

• Young Physician Focus: A little help from my friends

• Isotretinoin management: Store-and-forward vs. live-interactive telemedicine

• Derm Coding Consult: Audits for skin biopsies, repairs on the rise

• Share examples of patient harm caused by early release of electronic health information

April 14, 2021:

• Pulsed dye laser versus ablative fractional CO2 laser for hypertrophic scars

• DermWorld Insights and Inquiries: LIDA rose the insulin requirement

• Actinic keratosis clinical guideline published

• Do mucocutaneous eruptions correlate with COVID-19 severity?

• What do consumers recall from sunscreen labels?

April 7, 2021:

• Applying 2021 E/M coding concepts in everyday practice – Part 2

• DermWorld Insights and Inquiries: Keeping an eye on melanoma

• AAD collaborates with OM1 to enhance DataDerm™

• Phase III results revealed for molluscum contagiosum treatment

• AADA advocates for improved safety oversight for dermal fillers

• Your patients can help the Academy raise awareness about skin cancer

• Payment Protection Program extended

March 31, 2021:

• Studies show skin rashes are highly predictive of positive COVID-19 results

• DermWorld Insights and Inquiries: Netherton syndrome — From apex to nether

• New AAD research grant focuses on understudied hair disorders

• How does COVID-19 impact patients with bullous pemphigoid, pemphigus?

• FDA accepts AADA’s recommendation to improve access to quinacrine

• The AAD Virtual Career Fair is virtually here!

March 24, 2021:

• Derm Coding Consult: Applying 2021 E/M coding concepts in everyday practice — Part 1

• DermWorld Insights and Inquiries: Lipschütz ulcers — Not only for women

• Imiquimod vs. photodynamic therapy for actinic keratosis of the scalp

• No more waiting on EHRs for MIPS!

• Is mycophenolate mofetil effective for the treatment of cutaneous lichen planus?

• Does maternal autoimmune disease have an impact on offspring?

March 17, 2021:

• COVID-19 in melanoma patients

• DermWorld Insights and Inquiries: Hoops and happiness — Having the courage to take a shot

• DermWorld Young Physician Focus: Forging ahead

• Chemical peels for melasma in patients with skin of color

• Monitoring patients on methotrexate for lab abnormalities

• Vitiligo patients share struggles, therapeutic needs with FDA

March 10, 2021:

• Periungual warts: Is intralesional antigen immunotherapy effective?

• DermWorld Insights and Inquiries: A shot in the dark

• How does baricitinib fare in alopecia areata?

• Do calcineurin inhibitors, phototherapy have a risk of skin cancer, lymphoma?

• UHC extends application deadline for Designated Diagnostic Provider Program

March 3, 2021:

• The latest on the association between diet and acne

• DermWorld Insights and Inquiries: Time to reassess messing around with steroids and psoriasis

• Is intralesional 5-FU effective for nonmelanoma skin cancer?

• Topical CBD for skin conditions: The known and unknown

• 2021 AAD election: View ballot book, prepare to cast vote

• CMS announces automatic exemption for MIPS 2020 performance period, extended deadline for COVID relief

• When is repayment due for CMS' advance payment program?

Feb. 24, 2021:

• COVID-19 vaccination for patients on immunotherapies: An evidence-based guide

• DermWorld Insights and Inquiries: Multiple pilomatricomas by the numbers

• DermWorld Young Physician Focus: Do you take the ‘wait and see’ approach in your practice?

• FDA approves HA dermal filler for chin retrusion

• United to roll out new Designated Diagnostic Provider program; deadline to apply Feb. 28

• Short-term PPP window open for smaller businesses

• Meet the candidates for the 2021 AAD election

Feb. 17, 2021:

• FDA approves cemiplimab for advanced BCC

• DermWorld Insights and Inquiries: Honing in on diffuse dermal angiomatosis

• New JAK inhibitor shows notable PASI score improvement

• Physician perceptions of people with disabilities

• Minocycline foam label updated with new data

• CDC issues quarantine recommendations for vaccinated health care workers

Feb. 10, 2021:

• FDA clears device to improve cellulite

• DermWorld Insights and Inquiries: Leishmania episode 1a — attack of the clones

• Distance traveled: Dr. Lim’s diversity focus as Academy president still relevant today

• Treating vitiligo with apremilast and narrowband UVB in skin of color

• Isotretinoin vs oral antibiotics: Risk of depression

Feb. 3, 2021:

• How effective are oral hair growth supplements?

• DermWorld Insights and Inquiries: Going green — The complexities of the green nail syndrome

• A practical guide for managing hidradenitis suppurativa patients

• ABD selects new executive director

• How effective are educational brochures at encouraging skin cancer screenings?

• Academy Advisory Board invites members to submit policy resolutions

Jan. 27, 2021:

• Can dermatology employers require employees to receive the COVID-19 vaccine?

• DermWorld Insights and Inquiries: Playing the field — Introducing tirbanibulin for actinic keratosis therapy

• DermWorld Young Physician Focus: Settling into the New Year

• FDA grants orphan drug designation for advanced melanoma treatment

• Vitiligo and dementia: Is there a connection?

Jan. 20, 2021:

• Natural supplements in dermatology: What drugs do they interact with?

• DermWorld Insights and Inquiries: Olmsted syndrome patients can finally put their foot down

• Derm Coding Consult: UnitedHealthcare delays Laboratory Test Registry until 2022

• Vaccinating patients on TNF inhibitors

• FDA’s Bad Ad Program offers CME opportunity

• Academy Advisory Board invites members to submit policy resolutions

Jan. 13, 2021:

• CMS implements congressionally mandated adjustments, avoiding steep Medicare cuts

• DermWorld Insights and Inquiries: Not aging like fine wine — The myths and mysteries of acquired port wine stains

• PPP loan forgiveness 101

• How should dermatologists decide which patients get in-person appointments during a pandemic?

• Have stretch marks finally met a worthy foe?

• COVID-19 public health emergency extended

Jan. 6, 2021:

• Managing pain in hidradenitis suppurativa patients: A proposed algorithm

• DermWorld Insights and Inquiries: Itching to see if polymerase chain reaction mite be the future of diagnosing scabies

• 2021 E/M guidance sunscreen update

• Does exercise affect papulopustular acne?

• COVID-19 Dermatology Registry accepting vaccine side effect submissions

• Academy seeks statements on proposed bylaws amendments

Dec. 23, 2020:

• The impact of COVID-19 on the practice of dermatology

• DermWorld Insights and Inquiries: Holiday greeting 2020

• HHS announces additional Medicare relief funding

• FDA approves topical AK treatment

• Young Physician Focus: Bidding 2020 farewell (and good riddance!)

• Three cases of facial swelling reported in Moderna vaccine trial

• AAD members among Medscape’s 25 Rising Stars

• iPledge callers experience long wait times

Dec. 16, 2020:

• What are risk factors for frontal fibrosing alopecia?

• DermWorld Insights and Inquiries: We’re in hot water! Vibrio vulnificus infections are heading north.

• Anti-kickback statute implications for company-speaker programs

• Information blocking rule: What does it mean?

• Academy seeks statements on proposed bylaws amendments

• FDA shares voluntary topical drug product recall

Dec. 9, 2020:

• What are the effects of OTC moisturizers on skin barrier function?

• DermWorld Insights and Inquiries: Much ado about nothing in dermatopathology

• CMS fails to prevent Medicare cuts, E/M payment changes move forward

• ABMS Draft Standards for Continuing Certification Call for Comments delayed until April 2021

• Participate in the COVID-19 Dermatology Registry

• Academy seeks assistant secretary-treasurer nominees

• Deadline extended for MIPS extreme and uncontrollable circumstances application

Dec. 2, 2020:

• Surgical vs non-surgical interventions for basal cell carcinoma

• DermWorld Insights and Inquiries: Pigmented onychomatricoma — Avoid getting nailed by misdiagnosis

• Derm Coding Consult: Coding for preventive skin examination in 2021 and beyond

• MIPS dates and deadlines: What you need to know

• How thoroughly are biosimilar products tested?

• Hurricane Laura, wildfires qualify as national disasters, receive neutral payment adjustment

Nov. 18, 2020:

• Hydrogen peroxide and the common wart: Phase 2 results are in

• DermWorld Insights and Inquiries: Granulomatous slack skin — More than one type of mimicry

• FDA loosens restrictions on compounding in physician offices

• DermWorld Young Physician Focus: You are what you consume

• Deadline for MIPS extreme and uncontrollable circumstances application approaching

• FDA releases microneedling device guidance

Nov. 11, 2020:

• How effective are steroid-sparing agents in treating chronic alopecia areata?

• DermWorld Insights and Inquiries: Raising a toast to advances in treating alcohol-induced flushing

• Derm Coding Consult: Coding for office visit evaluation and management (E/M) in 2021 and beyond: FAQs

• FBI warns of cybercrime threat to health care providers, hospitals

• Can dermoscopy be used to evaluate skin barrier repair?

• Academy seeks assistant secretary-treasurer nominees

Nov. 4, 2020:

• FDA approves OTC head lice lotion

• DermWorld Insights and Inquiries: Striving to alleviate the physical and emotional scars of central centrifugal cicatricial alopecia

• The future of telehealth

• New EHR interoperability rule delayed

• Derm Coding Consult: Payers to reinstate cost-sharing requirements for virtual appointments

• Rejected VA claims can now be appealed

• FDA, UMD seek feedback on compounded drug use

Oct. 28, 2020:

• Drug may offer prolonged improvement in chronic spontaneous urticaria

• DermWorld Insights and Inquiries: Looking into the whites of the mouth

• Why will dermatology experience a 2% payment reduction in 2021?

• Young Physician Focus: Help wanted

• Derm Coding Consult: Updated NCCI edits now available

Oct. 21, 2020:

• Can medical scribes boost physician profits?

• DermWorld Insights and Inquiries: Can topical ketoconazole tip the scales for acne vulgaris?

• Providing equitable dermatologic care for people with disabilities

• Got a story to tell? Share it in DermWorld!

• E/M coding for 2021: Major changes ahead

• FDA, UMD seek feedback on compounded drug use

Oct. 14, 2020:

• OTC scar treatments: What does the evidence say about efficacy?

• DermWorld Insights and Inquiries: Studying skin aging never gets old — The potential role of oxytocin

• Medicare advance payment program receives repayment extension

• Virtual group election period open for MIPS 2021

• Reducing pain, anxiety for dermatologic procedures using local anesthesia

• FDA, UMD seek feedback on compounded drug use

Oct. 7, 2020:

• The costs of prior authorizations in a dermatology department

• DermWorld Insights and Inquiries: Targeted anti-complement therapy may prove to be a complementary treatment for bullous pemphigoid

• Derm Coding Consult: CMS modifies the 60-day limit for locum tenens during COVID-19

• California Governor signs nurse practitioner independent practice law

• Can COVID-19 be transmitted via wounded skin?

• HHS announces new provider relief payments

• Academy seeks assistant secretary-treasurer nominees

Sept. 30, 2020:

• Private equity in dermatology, health care grows

• DermWorld Insights and Inquiries: New data to recall when considering radiation recall dermatitis

• Young Physician Focus: Prepping for round two

• Practicing cosmetic dermatology during COVID-19

• FDA, UMD seek feedback on compounded drug use

• FDA rule allows drug importation from Canada to lower drug prices